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Growing ageing population has become a worldwide concern to healthcare 
systems. Chronic heart failure and osteoporosis represent two major age-related 
health risks. The pathogenesis of the two diseases is likely to be multi-factorial 
with oxidative stress, whether originating from pathologies or age-related 
accumulation, being a key player. Pharmacological management of the two 
conditions is largely symptomatic and is confined by various side effects, 






-adenosine triphosphatase (NKA) is the first P-type ATPase ever 
identified. The role of NKA in cardiac physiology has been well elucidated and 
exploited by the positive inotropic drugs such as cardiac glycosides. The role 
NKA plays in bone, however, remains largely unknown. Growing in vitro and in 
vivo evidence has confirmed that excessive ROS results in loss of NKA 
expression and activity. In consideration of the pivotal role of ROS in 
cardiovascular and skeletal conditions, as well as the consistent observation of 
reduced NKA in failing myocardium, it is hypothesized that the loss of NKA 
under oxidative stress is closely associated with pathogenesis of heart failure and 
osteoporosis, and that stabilization of NKA with an antibody specific to its 
DR-region (DR-Ab) may prove therapeutic to the diseases.   
Here, DR-Ab was shown to protect cardiomyocytes and osteoblasts from 
oxidative injury. The protection was mediated by stabilizing functional NKA 
against its aberrant endocytosis during oxidative stress. Suppressed activity of 
 xiv 
 
protein phosphatase 2A was responsible for the loss of membrane NKA due to 
increased phosphorylation of key serine residues that triggered endocytosis. 
Incubation with DR-Ab restored PP2A activity and maintained NKA expression 
on the plasma membrane. Inhibitors of PP2A abolished the protective effect of 
DR-Ab against oxidative stress. 
The cytoprotective effect of DR-Ab was verified in vivo. In heart, DR-Ab 
significantly reduced the infarct size and improved the impaired heart contractile 
function during ischemia and myocardial infarction-induced heart failure. 
Furthermore, DR-Ab induced stronger contraction in cardiomyocytes. The 
cardioprotective and positive inotropic properties of DR-Ab clearly indicated its 
therapeutic potential to treat heart failure.  
In bones, an important physiological function of NKA in osteoblast proliferation, 
differentiation, and viability was demonstrated for the first time. Moreover, the 
intriguing discovery that oxidative stress resulted in impaired NKA expression 
and function further pinpointed NKA’s critical role in the development of 
osteoporosis. Results of in vivo and ex vivo µCT scanning suggested that 
circulating DR-Ab effectively rescued the loss of trabecular bone and the 
deterioration of micro-architecture in osteoporotic rats, leading to increased bone 
strength. 
In sum, these data indicated that loss of NKA may contribute to cardiac and 
skeletal pathologies. DR-Ab, by stabilizing membrane NKA, protected 
cardiomycotes and osteoblasts against oxidative injury. More importantly, DR-Ab 
improved cardiac function in failing hearts and retarded osteoporosis development. 
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These findings, thus, provide new mechanistic insight to the pathogenesis of heart 





















LIST OF TABLES 
 








































LIST OF FIGURES 
 





Figure 2. Crosstalk between osteoblast (OB) and osteoclast (OC)………………17 
Figure 3. Interaction of the α- and β-subunits at the extracellular space and 
conserved sequence of the DR region……………………………………………23 
Figure 4. DR-Ab binds to and activates NKA from rat and mouse tissues……53 
Figure 5. Protective effect of DR-Ab against ROS injury in AC16 cells………55  
Figure 6. Protective effect of DR-Ab against ischemia reperfusion injury in 
isolated cardiomyocytes and hearts……………………………………………58  
Figure 7. Effect of H2O2 and ischemia/reperfusion on plasma membrane NKA 
activity and abundance…………………………………………………………...60  
Figure 8. Endocytosis of NKA is responsible for reduced NKA on plasma 
membrane………………………………………………………………………...62  
Figure 9. Protein phosphatase 2A (PP2A) is involved in H2O2-induced NKA 
endocytosis……………………………………………………………………….64 
Figure 10. Stabilization of NKA on plasma membrane via PP2A activation 
mediates protective effect of DR-Ab…………………………………………….66  
Figure 11. Effect of DR-Ab on the myocyte contractility……………………….69  
Figure 12. Effect of DR-Ab on the intracellular Ca
2+
 transients………………...70  
 xviii 
 
Figure 13. Preservation of cardiac function by DR-Ab following ischemia 
reperfusion injury in isolated hearts……………………………………………...72  
Figure 14. Establishment of heart failure rat model by myocardial infarction…..74  
Figure 15. Effect of DR-Ab on contractile function in heart failure rats………...76  
Figure 16. Effect of DR-Ab on isoproterenol (ISO) induced heart failure and 
NKA reduction…………………………………………………………………...79 
Figure 17. Effects of DR-Ab on H2O2-induced injury in MC3T3-E1 osteoblastic 
cells………………………………………………………………………………81  
Figure 18. Effects of DR-Ab on H2O2-suppressed differentiation of MC3T3-E1 
osteoblastic cells…………………………………………………………………83 
Figure 19. Effect of DR-Ab on osteoclast differentiation………………………..85  
Figure 20. PP2A mediates the effect of DR-Ab…………………………………87 
Figure 21. PP2A interacts with the N-terminus of NKA………………………90  
Figure 22. Effect of DR-Ab in H2O2-induced loss of membrane NKA via 
endocytosis……………………………………………………………………….92  
Figure 23. PP2A mediates the inhibition of DR-Ab on NKA endocytosis……...93  
Figure 24. Loss of NKA impairs osteoblastic cell differentiation and                       
viability………………………….……………………………………………….95  
Figure 25. Effect of DR-Ab on trabecular bone loss in OVX rats……………..97  
Figure 26. DR-Ab improved mechanical properties of the bones in OVX rats...100  
 xix 
 
Figure 27. Effect of DR-Ab on OVX-induced bone turnover………………….102  
Figure 28. Effect of DR-Ab on reduced NKA expression in OVX rat bones….104  
Figure 29. Effect of long term (4 month) circulating DR-Ab on the cardiac system 
in OVX rats……………………………………………………………………..106 




















































1.1 General introduction of Na+-K+-ATPase (NKA) 




-adenosine triphosphatase (NKA) is the first 
P-type ATPase ever identified 
1
 and remains the most prominent member of this 







-ATPase, plasma membrane proton pump and others 
2
. For one transport 
cycle driven by the hydrolysis of a molecule of ATP, three Na
+
 ions are exported 
out of the cells in exchange for two K
+
 ions into the cells against chemical 
gradient 
3-4
. Such ion transport is accompanied by different NKA conformations, 
in particular, the highly selective sodium-bound E1 state 
5
 and the less selective 
potassium-bound E2 state 
6
.  As a result, both ion and electrochemical gradients 
are created and maintained by the activity of NKA and are essential in many 
physiological processes, such as the maintaining of membrane resting potential 
and generation of action potentials along nerves 
7
, providing driving force for 
secondary active transporters 
8-9
, as well as regulating cell volume and pH.  
NKA is a transmembrane enzyme ubiquitously expressed in all animal cells. 
Functional NKA is a heterodimeric protein composed of a 100kDa α-subunit and 
a 55 kDa β-subunit 10. The α-subunit is a 10-span class IV membrane protein that 
bears all domains related to the activity of NKA, e.g. the binding sites for cations, 
ATP and phosphates, and the inhibitory cardiac glycosides 
11. The β-subunit, on 
the other hand, is a single spanning class II membrane protein important in the 
correct membrane integration and packing of the catalytic α-subunit. Apart from 
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being a chaperone, β-subunit also plays a role in the transport properties of NKA 
12
. In addition, NKA contains a 70-180 amino-acid auxiliary regulatory subunit, 
which are tissue specifically expressed 
13
. This subunit belongs to the FXYD 
proteins, a group of hydrophobic type I polypeptides sharing structural similarities 
14-18
. A structural illustration of the NKA is provided in Figure 1. 
 
 




-ATPase. (A) Schematic depiction of the 
arrangement of the NKA α/β complex with the γ-subunit. The cytoplasmic 
domain connecting transmembrane (TM) helix 2 and 3 contains the main part of 
the A-domain. The cytoplasmatic domain connecting TM helix 4 and 5 harbors 
the N- and P-domain. (B) Structure of NKA in the [Rb2]:E2:MgF4
2-
 state. (C) 
Structure of NKA in the E2P state with ouabain bound. Color code: Grey: TM 
region of the α-subunit; Red-brown: TM region of the β subunit; Orange: TM 
region of the FXYD2 protein (also known as γ-subunit); Yellow: the actuator (A-) 
domain; Red: nucleotide binding (N-) domain; Blue: phosphorylation (P-) domain; 
Cyan spheres: Rb
+







In humans, there are four known isoforms of α-subunit (α1, α2, α3, and α4). The 
α1-isoform is the predominant isoform and is ubiquitously expressed 20; the 
α2-isoform is mainly found in skeletal, heart, and smooth muscle 21-22, brain 23, 
and adipocytes tissue 
24; the α3-isoform has a neuron-specific distribution 23, with 
the exception of some species in which it can be found in the heart 
21
; and the 
expression of α4-isoform is localized in testis at the spermatogonia 25-26. Three 
isoforms of β-subunit (β1, β2, and β3) have been identified so far. The β1-isoform 
can be found in most tissues 
27, constituting the most abundant α1/β1 NKA 
subtype; the β2-isoform is mainly expressed in neuronal tissues 28-29; and the 
expression of β3-isoform is largely confined in rat lung and testis, despite its 




, and peripheral bold cells 
32
. Seven FXYD proteins have been identified. Evidence suggests that majority of 
them are tissue-specifically expressed and modulate NKA kinetic properties when 
they are associated with various α/β complex 17. The list of NKA subunit isoforms 









 across the membrane, NKA also relays extracellular 




ouabain (a cardiac glycoside) signal to intracellular compartments via activation 
of different protein kinases 
33-34
. Tyrosine kinase of the Src family is activated 
upon ouabain binding to NKA, resulting in downstream protein tyrosine 
phosphorylation 
35-36
. Some downstream substrates for activation include the 
signaling cascade Ras/Raf/ERK1/2, which leads to stimulated reactive oxygen 
species (ROS) generation, and protein kinase C (PKC) isozymes. Intracellular 
calcium concentration is also regulated by this signaling network 
37
. Later, 
phosphatidylinositol 3-kinase (PI3K)-Akt pathway was demonstrated to be 
involved in the ouabain-induced activation of NKA 
38
 in association with the 
established Src-mediated pathway. Moreover, growing evidence suggests that 
NKA plays an important role in cell adhesion, for that the β-subunit has a 
K
+
-dependent adhesion activity 
39
. In cancers, NKA expression and activity have 
been shown to be aberrant and may be implicated in the disease development and 
progression 
40




1.2 Congestive heart failure 
1.2.1 Epidemiology of congestive heart failure 
Congestive heart failure (CHF) defines the impaired ability of the heart to supply 
sufficient blood flow to meet the body’s needs 42. Clinically, CHF is a syndrome 
characterized by breathlessness, fatigue, and sodium and water retention due to 
cardiac, usually ventricular dysfunction.  
 7 
 
Heart failure is becoming an increasing threat to human health conditions. In the 
United States alone, approximately 5,700,000 (3,100,000 males and 2,600,000 
females) adults aged 20 and older suffer heart failure, the common pathway of 
many cardiovascular diseases, and 670,000 new cases are diagnosed each year 
43
. 
The lifetime risk of developing heart failure is roughly one in five for someone 
aged 40 years 
44-45
. Despite advances in management of heart failure, the 1-month, 
1-year, and 5-year mortality rates after patients are hospitalized are 10%, 22%, 
and 42%, respectively 
46
, leading to about 300,000 deaths per year 
47
. Besides the 
high mortality, the extensive medical attention required by heart failure patients 
poses enormous burden on social health services, accounting for about 2% of all 
health-care spending 
48
. In 2010, the estimated total direct and indirect cost of 
heart failure mounts up to $39.1 billion 
47
.   
 
1.2.2 Risk factors and pathophysiology of CHF 
Heart failure can be classified into diastolic and systolic types. Diastolic heart 
failure refers to the perturbed diastolic relaxation due to the stiffened cardiac 
muscle. Systolic heart failure represents reduced ejection fraction as a result of the 
weakened left ventricle. To date, systolic heart failure has been extensively 
studied and is the target of most current therapies and clinical trials 
49
. For the 
purpose of this study, we mainly focused on systolic heart failure. 
Coronary disease is one of the most important and thoroughly studied causes of 
systolic heart failure in developed countries 
50-51
, accounting for more than 60% 
of the CHF patients in the US 
52
. With occluded coronary artery, both reversible 
 8 
 
and irreversible cardiac injuries occur, depending on the duration of the ischemia 
53
. The most likely reason accounting for myocyte death during ischemia is the 
disrupted integrity of sarcolemma, which results in leaking of intracellular 
components to the extracellular space 
53
. In addition, energy metabolism is likely 
to be affected by ischemia 
54-55
. The injury may be aggravated by the 
compromised microvasculature following the death of endothelial cells of the 
capillaries, which prevents the entry of arterial blood and drugs into the ischemic 
region 
56
. Reperfusion of ischemic myocardium causes myocardial injury at an 
extent far greater than that induced by ischemia alone 
57
. With reintroduction of 
oxygenated blood, the ischemic myocardium experiences several biochemical and 
metabolic changes, including generation of excessive amount of ROS, Ca
2+
 
overload, rapid pH change, and inflammation 
58-59
. ROS induce mitochondrial 
permeability transition pore opening, attract neutrophils, mediate sarcoplasmic 
reticulum dysfunction, cause oxidative damage to lipid, protein, and DNA, as well 
as afford Ca
2+
 overload, all of which contribute to myocardial injury 
58
. Besides 
necrosis, ROS also triggers apoptosis by activating the pro-apoptotic signaling 
pathways 
60-61
. The role of autophagy during reperfusion remains at debate in that 
no consensus has been reached whether autophagy promotes cell survival or 
augments cell death 
62
. Overall, extensive damage to cardiomyocytes and loss of 
cell viability occur in ischemic hearts 
63
.  
Necrotic cells elicit an inflammatory response by releasing into circulation some 
intracellular contents which are detected by the immune system as markers of 
injury. Dead myocytes are removed by the immune cells, followed by fibroblasts 
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proliferating and secreting extracellular matrix proteins to form fibrotic scar. The 
remodeling continues to progress, leading to hypertrophy, wall thinning, chamber 
dilation, and heart failure 
64
.  
Although recent evidence suggests the existence of heart progenitor cells that are 
capable of reentering the cell cycle and proliferate to replace dying 
cardiomyocytes, contradicting the long-held idea that the heart is strictly 
postmitotic 
65-70
, it is recognized that in the setting of injuries, these progenitor 
cells are unable to replace the dying cardiomyocytes and prevent tissue loss 
49
. 
Because cardiomyocytes are responsible for the contractile function of the heart, 
loss of viable cardiomyocytes leads to weakened ventricle. And preservation of 
viable cardiomyocytes is vital in maintaining proper heart functions. In fact, 
inhibition of myocyte death has been shown to prevent the development of 
cardiac dilation and contractile dysfunction 
71
. Moreover, blockers of angiotensin 









, cardiac fibrosis 
75-77
, vascular heart diseases 
52
, as well as lifestyle 
factors like the use of cardiotoxic substance 
78
, smoking, low physical activity and 
overweight 
52
. Male sex and lower education levels could also contribute to the 
development of heart failure 
52




1.2.3 Current pharmacological treatment of CHF and limitations 
A number of therapeutic agents are currently used in treating heart failure, 
including angiotensin converting enzyme inhibitors, angiotensin receptor blockers, 
beta-adrenergic agonists and antagonists, aldosterone antagonists, and diuretics. 
These drugs manifest significant therapeutic effects in reducing morbidity and 
mortality 
79
 via decreasing preload and/or afterload of the heart by dilating 
vascular tone, inhibiting heart oxygen consumption or decreasing blood volume. 
Another group of drugs are the cardiac glycosides (e.g. ouabain, digitalis and 
digoxin), which directly improve cardiac function in the failing hearts 
80
. These 
drugs, however, produce severe toxic effects including cardiac arrhythmias, 
gastrointestinal and central nervous system disorders. Cardiac glycoside 
associated toxicity can be induced by overdose, as well as by drug interactions or 
patients’ pathophysiological conditions, making monitoring of plasma drug level 
necessary in clinical settings. However, accurate dose monitoring is difficult for 
the presence of endogenous digoxin-like-immunoreactive substances and the 
decreased NKA level in heart failure patients. Cardiac glycosides are therefore 
limited in clinical uses by the narrow therapeutic window and the development of 
new drugs for CHF is needed. 
 
1.3 NKA in healthy and failing hearts 
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1.3.1 NKA in heart physiology 









]i) through Na/Ca exchanger (NCX), which is the main export route of Ca
2+
, 
playing a key role in Ca
2+
 clearance. With an increased concentration of [Na
+
]i, 




 efflux), leading to 
elevated [Ca
2+
]i and subsequently, Ca
2+
 release from sarcoplasmic reticulum (SR) 
at diastole. This not only reduces the availability of Ca
2+
 in intracellular store, 
which is crucial in systole 
81
, but also contributes to Ca
2+
-dependent contractile 
abnormalities and arrhythmias that characterize heart failure 
82-83
. NKA provides 




, therefore, allowing 




]i to prevent their overload and 
subsequent arrhythmias. 
 
1.3.2 Ouabain and cardiac glycosides 
Cardiac glycosides, also known as cardiotonic steroids, have long been used to 
treat chronic heart failure by inducing failing heart muscle to contract stronger. 
Originally, only exogenous cardiac glycosides extracted from plants of the genus 
Digitalis, from the bark of Acokanthera ouabaio or the seeds of African 
Strophanthus gratus, and several species of toads, were known. A common 
general structure was found in the cardiac glycosides with a five- or 
six-membered lactone ring attached to a steroid nucleus 
85-86
. In 1991, for the first 
time, an endogenous cardiac glycoside, ouabain, was discovered in human 
87
. 
Many more endogenous cardiac glycosides have followed ever since and 
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researchers have devoted enormous attention to study the role of NKA in 
physiological and pathophysiological processes by employing cardiac glycosides, 
especially ouabain, as a powerful tool 
88
. Today, cardiac glycosides are considered 
responsible not only in blood pressure regulation but also in cellular functions 
such as proliferation and differentiation 
87,89-91
.  
Traditional view of the mechanism underlying the positive inotropy induced by 
cardiac glycosides states that these drugs inhibit the function of NKA, leading to 
an increase in intracellular Na
+





-exchanger (NCX) is affected by the accumulation of sodium inside cells 
and the intracellular Ca
2+
 concentration rises, which ultimately induces stronger 




1.3.3 NKA in heart failure 
Given the importance of NKA in heart electrical and contractile function, the 
regulation of NKA expression and activity in heart has drawn substantial research 
interest. Numerous observations have long associated decreased NKA activity and 
expression with heart failure. In a myocardial infarction-induced heart failure rat 
model, Semb et al. reported aberrant concentration of α2 and α3 isoforms 95. On 
the contrary, Spinale et al. found in tachycardia-induced cardiomyopathy pigs that 
the density of NKA significantly fell without affecting that of α2 and α3 isoforms 
96
. Examination of biopsies from dilated cardiomyopathy patients showed 
significant decrease in NKA concentration as compared to patients with normal 
left ventricle functions (331±19 vs. 559±62 pmol/g wet weight) 
97
. In another 
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clinical study, an approximately 25% reduction of NKA concentration was found 
in heart failure associated with heart dilation, myocardial hypertrophy, and 
ischemic heart disease, with possibly an additional 15% reduction in patients 
receiving digoxin treatment 
98
. Biopsy specimen obtained from right ventricles of 
patients with end-stage idiopathic dilated cardiomyopathy showed lower 
concentration of NKA compared with control specimens (425±80 vs. 498±75 
pmol/g wet weight) 
99
. In the same year, a comparison between failing hearts and 
donor hearts for transplantation found a drastic decrease in NKA α1, α3, and 
β1-isoform 100. It is worth noting that the amount of reduction varies across studies. 
For example, Allen et al. reported no statistically significant alteration in the 
expression of NKA in heart failure patients, although a decreasing trend was 
found 
101
. This could be due the different stages of myocardium disease when the 
specimens were collected, as well as relatively small sample size and inaccuracy 
in the method. Nevertheless, a conclusion could be drawn that a consistent 26-32% 
reduction in NKA protein level and activity in human failing hearts exists across 
available studies 
100,102
. The reduction of NKA in failing myocardium perhaps 
explains the increased sensitivity of heart failure patients to cardiac glycosides 
102-103
. 
Although the association between reduction in myocardium NKA and heart failure 
has been well established, it was not until recently a direct causal relationship was 
proposed. Using heterozygous NKA (α1+/-) mice and neonatal rat cardiomyocytes, 
NKA is shown to be involved in the etiology of cardiac dysfunction, and reduction 





Together, reduced NKA activity and expression is clearly associated with the 
viability of cardiomyocytes and various cardiac conditions, making stabilization 




1.4.1 Epidemiology of osteoporosis 
Osteoporosis is defined as a skeletal disorder characterized by reduced bone mass 
and deteriorated microarchitecture that predispose affected individuals to higher 
risks of fracture 
105-106
. More specifically, the World Health Organization (WHO) 
defines the diagnosis of osteoporosis as a bone mineral density (BMD) value 
significantly deviating (≥2.5 standard deviations) below a reference BMD value 
measured in a group of 30-year-old women 
107-108
.    
Osteoporosis is a common condition in women after menopause due to 
accelerated loss of bone without estrogen. It may also develop in men, or anyone 
with particular hormonal disorders or other conditions that require chronic 
glucocorticoid medications. In USA alone, 10 million individuals are estimated to 
have osteoporosis, and 80% of them are women. More resistant to the condition, 
the prevalence of osteoporosis in men is about 4-6% over the age of 50. 
Combined with up to 3 times as many individuals who have osteopenia and thus 
are at risk for osteoporosis, reduced bone mass affects more than half of the US 
population aged 50 and above 
109-110
. The most common manifestation of 
osteoporosis is fragility fractures, with hip fracture and vertebral compression 
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fracture being the most devastating complications 
111
. The lifetime risk of fracture 
in women and men is about 50% and 13-25%, respectively 
112
. The situation is 
worsened by the fact that those who suffer from fractures are three- to four-fold 
more likely to have future fractures 
109,113
. Worldwide, it is estimated that 200 
million people are suffering from osteoporosis 
114
.  
The socio-economic impact of osteoporosis is immense, considering that 
osteoporosis and resultant fractures significant compromise patients’ quality of 
life and require extensive financial expenditure. In 2005, fragility fracture 
incurred 2.5 million visits to medical office, 430,000 and 180,000 admissions to 
hospital and nursing homes, respectively, costing $19 billion 
115
. Moreover, 
follow-up studies revealed that 22% of patients were admitted to nursing home in 
seek for additional medical care within a year of their fragility fracture 
116
.   
As osteoporosis is an age-related condition, aging societies are likely to see a 
steep incline in the prevalence of osteoporosis. In the US, for example, the 
population aged 50 or older is projected to grow by 60% to 120 millions in 2025 
117
. Accompanying the growth of aging population is the increase in fractures and 
associated costs by almost 50% by 2025 
115
. The trend of increasing population of 
the elderly and fractures can be found in Europe, Japan, and China, aggravating 
the already overburdened public healthcare system.  
 
1.4.2 Pathology of osteoporosis 
Osteoporosis has many risk factors, including but not limited to age, gender, 
genetics, and lifestyle differences 
118
. Since menopause was linked with 
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osteoporosis in the 1960s, estrogen deficiency has been the most extensively 
studied model that causes bone loss 
119
. Under normal conditions, bones are 
subject to constant remodeling, during which old bone is replaced by new bone. 
To begin the remodeling process, bone-resorbing osteoclasts are recruited to the 
bone surface, which then, secrete hydrogen ions to acidify and dissolve the 
mineralized bone matrix. Following the resorption of bones, osteoclasts undergo 
apoptosis and leave room for the bone-forming osteoblasts to be recruited to 
surface of the bone. Osteoblasts synthesize collagen and other proteins that 
comprise the organic matrix of bone, as well as deposit calcium and 
phosphate-based mineral into the matrix to form the new bones. In healthy bones, 
this remodeling process is regulated by a finely orchestrated effort of osteoclast 
and osteoblast, acting in what has been named the basic multicullar unit (BMU). 










Figure 2. Crosstalk between osteoblast (OB) and osteoclast (OC). (A) OB 
lineage cells secrete MCSF (macrophage colony stimulating factor) and RANKL 
that induce differentiation of OC from OC precursors (OCP). OCs, during bone 
resorption, release growth factors like TGFβ and IGF1 from bone matrix, which 
recruit and promote differentiation of mesenchymal osteoblast pregenitors to 
mature osteoblasts and osteocytes. (B) OCs also produce clastokines that recruit 
and promote proliferation and differentiation of OB progenitors. (C) Cell-cell 
contact may mediate crosstalk of OB and OC. Communications via ephrins from 
OC and RANKL from OB are shown here. 







Estrogen deficiency topples the balance by increasing osteoclastic bone resorption 
without increasing osteoblastic bone formation correspondingly. The absence of 
estrogen stimulates osteoclastogenesis by increasing production of tumor necrosis 
factor (TNF) and sensitizing osteoblastic lineage to interleukin 1 (IL-1). Together, 
TNF and IL-1 trigger preosteoblasts to release a set of cytokines, including 
macrophage colony stimulating factor (M-CSF), granulocyte macrophage colony 
stimulating factor (GM-CSF), IL-6, IL-11, transforming growth factor (TGF), and 
RANKL (receptor activator of nuclear factor B ligand), which  positively 
influence osteoclast differentiation from their precursor cells. In addition, 
estrogen deficiency also elongates osteoclast lifespan by TGFβ-mediated 
suppression of apoptosis. Altogether, the result is a net loss of bone.  
 
Besides estrogen deficiency, age related changes should not be overlooked. The 
first notable change is a marked loss of calcium within the first 3-4 years post 
menopause 
119
. Later in the sixties, calcium absorption starts to be impaired, 
further contributing to calcium loss 
121
. As a result of calcium malabsorption, aged 
patients develop secondary hyperparathyroidism, which in turn, accelerates bone 
resorption. The faulty calcium absorption process is the result of both reduced 
production of 1,25-dihydroxyvitamin D in aging kidney, and decreased 
responsiveness to it in many people 80 years and older. Bone mineral density also 
decreases with age. Gradual bone loss begins even years before menopause, 
accelerating at the onset of menopause and the rapid bone loss continues for about 
3 years 
122
, before slowing down and stabilizing at a relatively high rate.  
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Besides estrogen withdrawal, reactive oxygen species (ROS) accumulation is 
another key contributor for osteoporosis. Both female and male mice lose BMD 
and bone strength with increasing age, and such deterioration is associated with 
accumulation of ROS and impaired antioxidant defense system 
123-124
. In 
ovariectomized rats, level of lipid peroxidation and hydrogen peroxide are 
increased with reduced enzymatic antioxidants such as superoxide dismutase 
(SOD), glutathione peroxidase (GPx), glutathione S transferase (GST) 
125
. 
Post-menopausal, age-dependent, and glucocorticoid-induced losses of bone mass 
have been associated with a progressive increase in ROS levels 
126-128
. In fact, 
advances in the understanding of osteoporosis have led to a paradigm shift from 




1.4.3 Current pharmacological treatment of osteoporosis and 
limitations 
In spite of its high prevalence, prevention and treatment of osteoporosis have been 
problematic. Current treatment regimens for osteoporosis fall into two categories: 
antiresorptive drugs that inhibit osteoclast function such as estrogen-receptor 
analogues, bisphosphates, selective estrogen reception modulators (SERMS), and 
Denosumab; and anabolic drugs that induce osteoblastic bone formation, namely 
parathyroid hormone. However, clinical usage of these drugs is limited by their 
side effects. For example, prolonged use of estrogen replacement is associated 
with complications including breast cancer, uterine bleeding, and cardiovascular 
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events, while bisphosphates are often held responsible for osteonecrosis of the jaw 
129-132
. Some SERMS are good replacement of hormone replacement, with similar 
side effect such as venous thromboembolism and hot flashes. Denosumab, a 
human monoclonal antibody approved by FDA in 2010, targets and inhibits 
RANKL in the bone resorption 
133
. The use of Denosumab poses higher risk of 
infections in various systems and joint pain 
134-135
, possibly due to the suppressed 
RANKL activity in the immune system 
136
. The prescription of anabolic drug PTH 
is also restricted by the potential incidence of osteosarcoma 
137
. Furthermore, 
some patients do not respond to these drugs, whether administered individually or 
in combination 
138-139
. Thus new treatments are needed for osteoporosis.  
Besides pharmacological management, there are other approaches as well. For 
example, calcium and vitamin D supplementation 
140-141
, protein intake 
142
, 
physical activity, and lifestyle change (e.g. quit smoking and alcohol consumption) 
have been shown to be beneficial for osteoporotic bones.  
 
1.5 NKA in osteoporosis 
Despite the extensive studies on NKA made in the last half a century, its 
physiological functions in bone remain mostly unknown. Estrogen withdrawal is 
by far the main factor for postmenopausal osteoporosis. Recent discoveries 
indicate that estrogen has a profound effect on the activity and expression of NKA. 
It has been demonstrated that 17β-estradiol enhances the activity of NKA in 
cardiac myocytes, neuron cells, and alveolar epithelial cells 
143-145
. 
Ovariectomized rats display decreased NKA expression and activity, which could 
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be remedied by 17β-estradiol supplement 146. Furthermore, in erythrocytes in 
women, the activity of NKA increases when estrogen levels reach a peak during 
the menstrual cycle 
147-148
.   
In light of the growing evidence that age-related oxidative stress contributes to 
osteoporosis, it is of particular interest to pinpoint NKA as a new confirmed target 
of ROS. Transgenic mutant SOD1 mice exhibit loss of NKA activity and protein 
149
. In vitro study of cells subjected ischemia-reperfusion revealed significant 
degradation of plasma membrane NKA as a result of the production of 
mitochondrial ROS 
150
. And it has been reported that the loss of NKA activity and 
expression due to ROS is largely accounted for by its endocytosis and degradation 
151
.  
Both estrogen withdrawal and ROS accumulation seem to converge at decreased 
NKA activity and expression. We, therefore, speculate that impaired NKA 
function may play a pivotal role in bone pathophysiology, in particular, 
osteoporosis.  
 
1.6 The DR region in NKA 
Functional NKA is a heterodimer of an α/β complex. The β-subunit of NKA, 
though not containing catalytic sites, interacts with the catalytic α-subunit to 
facilitate its resistance to cellular degradation, its acquisition of functional 
properties and its routing to the cell surface. To date, four regions in β-subunit of 
shark NKA have been identified to interact with α-subunit: Tyr 69-Tyr 83, Asn 
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182-Ile 185, Tyr 247-Lys 250 and Lys 290-Asp 291 (Figure 3A) 
152
. Of particular 
importance are the βTyr247 and βArg 183 residues, which form a salt bridge with 
the carboxy-terminal of the extracellular L7/8 loop in α sub 




 has been proposed 
to be a key site 
153




 (DR) which lies within the extracellular part of 
the α subunit 154 and contains a 901SYCQ904 sequence that is present in mammals, 






in some shark species (Figure 3B).  
A polyclonal antibody SSA412 targeting at the DR region activates NKA and 
results in positive inotropy in cardiomyocytes 
155
. Subsequent studies suggest the 
effect of SSA412 is mediated by enhanced influx of calcium ions through L-Type 
Ca
2+
 channel (LTCC), and Src/Erk1/2 signaling cascade is essential for the 
















1.7 Objectives, scope and significance 
With growing understanding of the role ROS plays in the pathogenesis of heart 
failure and osteoporosis, as well as that NKA may be a target of ROS, we 
Figure 3. Interaction of the α- and β-subunits at the extracellular space 
and conserved sequence of the DR region. (A) Conserved motifs are 
labeled with boxes. Four regions in the β-subunit are identified to interact 
with the α-subunit: Tyr69-Tyr83, Asn182-Ile185, Tyr247-Lys250 and 
Lys290-Asp291. In the α-subunit, DR region sits within the Asp892-Gln910 
motif, which interacts with βTyr247 and βArg 183. (B) The primary amino 
acid sequence of the DR region in NKA α1 isoform is conserved across 
species including rat, human, dog, sheep, and pig, with minor change in some 
sharks. The α2 and α3 isoforms show highly conserved sequence as the α1 
isoform. 





hypothesize that misregulation of NKA under oxidative stress is closely 
associated with the pathophysiology in cardiovascular and skeletal systems, and 
we develop an antibody that targets the DR-region of NKA (DR-Ab) as a tool to 
study this association. Furthermore, we investigated the potential therapeutic 
value of the DR-Ab in treating heart failure and osteoporosis. 
In this thesis, our work focuses on two parts:  
1). the in vitro effect of the DR-Ab under oxidative stress. Specifically, we 
examined the protective effect of the DR-Ab in (A) cardiomyocytes subjected to 
high ROS/ischemia reperfusion injury, and (B) osteoblastic cells subjected to high 
ROS challenge. We also performed experiments to reveal the underlying 
mechanisms with an emphasis on the altered NKA activity and expression as a 
result of ROS; 
2). the in vivo effect of the DR-Ab in (A) coronary disease-caused heart failure, 
and (B) ovariectomy-induced osteoporosis in rats.   
This work will add onto our understanding of NKA in cardiac pathology by 
showing beneficial effect of a stable level of NKA in maintaining of viable 
myocardium. In addition, this will be the first investigation on the 
long-overlooked role of NKA in bone (patho)physiology. More importantly, this 
work will demonstrate the possibility of targeting NKA to inhibit cell death under 
oxidative stress, thus proposing a new approach in the management of heart 










CHAPTER 2  















Material and methods 
2.1 The generation of a DR-region-specific antibody  
Adult Sprague–Dawley male rats (6-8 weeks) were immunized intradermally with 





) weekly for four times. The initial dose is 200 µg 
protein emulsified with CFA (complete Freund's adjuvant) per rat followed by 
100 µg protein emulsified with IFA (incomplete Freund's adjuvant) per rat every 
other week. The immunization generally takes 8 weeks (4 injections in total), but 
may be extended in animals with low antibody production. 5 days after the last 
immunization, rat was euthanized and all blood was collected from the heart. The 
blood was incuabated at 37°C for 30 min, and then centrifuged at 5000 g for 20 
min. The sera was stored at -80°C untill use. In some experiments, the rats were 
immunized with DR-peptide following the above protocol, and the effect of 
circulating DR-Ab was studied in these animals. 
For antibody purification, the Protein L resin column was first balanced by ten 
times volume of phosphate buffer (pH 7.2), and then the immuno sera was 
flowing automatically through the column. The unspecific protein was washed 
away by wahing buffer. Antibody was eluted with 0.1 M glycine (pH 3) and 
immediately adjusts eluted fractions to physiologic pH by adding 100 μl of the 1 
M phosphate (pH 8) to 1 ml of eluate. The elution was monitored by measuring 
the absorbance at 280 nm or by protein assay such as BCA™ Protein Assay Kit. 
The protein content of the purified fractions containing the antibody was 
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determined by BCA™ Protein Assay Kit, based on which the molarity was 
calculated by dividing it against the molecular weight of IgG (~150kD). 
To detect the titer of immunized sera and purified antibody, 96-well-plate was 
coated with DR peptide at the concentration of 1µg/well. The plate was blocked 
with 5% BSA for 1h at room temperature after coating with peptide at 4 °C 
overnight. The immunized sera and purified antibody were diluted in two-fold 
serial dilution, and then were incubated with coated DR peptides at room 
temperature for 2h. Bound antibody was probed with Goat anti-rat IgG labled 
with HRP (Horseradish peroxidase), followed by incubated with TMB (3, 3’, 5, 
5’-tetramethylbenzidine) for 15-30 min and read the optical density at 405 nm. 
The fractions of sera were stored at -80°C for future use. 
DR-Ab prepared in two batches was used in the experiments described in this 
thesis. DR-128 (coding representing the date of serum collection) was used in all 
in vitro and ex vivo experiments, while another batch of DR-Ab (DR-043) was 
used for introveneous injection in myocardial infarction-induced heart failure rats. 
To control for the inter-batch variation, DR-Ab from both preparations was 
compared in the protective effect against H2O2 in AC16 cardiomyocytes. 
Concentrations at which the two batches of DR-Ab produced similar protective 





All animal care and experimental procedures in this study were approved by the 
Institutional Animal Care and Use Committee of the National University of 
Singapore.  
 
2.3 Chemicals and Reagents  
PP2A antibody (#2038) was purchased from Cell Signaling (Danvers, MA 01923, 
USA). Alkaline phosphatase (ALP) antibody was purchased from Abcam 
(Cambridge, UK). Goat anti-rabbit, goat anti-mouse secondary antibodies, 
ImmunoCruz® mouse ABC staining system, and NKA-siRNA and scramble 
siRNA were purchased from Santa Cruz Biotechnology (Santa Cruz, CA95060, 
USA). Alexa Fluor 568 conjugated goat anti-rabbit IgG (H + L), and Alexa Fluor 
488 conjugated goat anti-mouse IgG (H + L) were from Invitrogen Corporation 
(Carlsbad, CA 92008, USA). NKA α1 antibody (464.6, ab7671) was purchased 
from Abcam (Cambridge, UK). The McK1 antibody was a generous gift from Dr. 
K. Sweadner (Massachusetts General Hospital, MA). SensoLyte® FDP Protein 
phosphatase assay kit was from AnaSpec, Inc (AnaSpec, Inc, Japan). 
Envision+system HRP (DAB), for use with rabbit primary antibody, was 
purchased from Dako (Glostrup, Denmark). LDH Cytotoxicity Assay Kit was 
purchased from Pierce Chemical (Rockford, IL, USA). All other reagents were 
purchased from Sigma Chemical Company (St. Louis, MO 63103, USA) or 




2.4 Purification of NKA 
NKA was purified from rat and mouse kidney outer medulla as described 
previously 
157
. Briefly, medulla slices were homogenized in a solution, containing 
(in mM) sucrose 250, histidine 30, imidazole 5, and EDTA 1 (4°C; pH 7.4), then 
centrifuged at 6000 g for 15 minutes in a Sorvall Legend Micro-21R centrifuge. 
The supernatant was re-spun at 15,000 g for 30 minutes at 4°C and the resultant 
supernatant was centrifuged at 150,000 g for 90 minutes (Beckman 
Optima
TM
L-90K T7; 4°C). The pellet was suspended in a homogenizing medium 
and incubated with SDS 0.4 mg per milligram protein per milliliter for 30 minutes 
at room temperature in the presence of 3 mmol/L ATP, 2mmol/L EDTA, and 50 
mmol/L imidazole, pH7.5. The resultant suspension was applied to discontinuous 
sucrose gradients, consisting of 0.32, 0.8, 1.0 and 1.2 mol/L of layers buffered with 
30 mmol/L of histidine and 5 mmol/L of imidazole (pH 7.4), and centrifuged at 
150,000 g for 120 minutes (Beckman Optima
TM
L-90K T7; 4°C). The pellet 
appearing at the bottom was resuspended in a homogenizing medium to a protein 
concentration 2 mg/ml, and stored at -80°C. 
 
2.5 NKA activity assay 
The effect of DR-Ab on NKA activity was using the following method as 
described previously 
158
. Purified rat NKA (10 mg/mL) was incubated in buffer 
(30 mM L-histidine, 100 mM NaCl, 20 mM KCl, 5 mM MgCl2, 10 mM 
2-mercaptoethanol, 0.06 mg/ml of phosphatidyl-L-serine, pH 6.8) with different 
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concentrations of DR-Ab at 37
o
C for 60 min. The reaction was initiated by adding 
Mg-ATP (3 mM) in a final volume of 0.2 mL at 37
o
C for 30 min and terminated 
by adding 0.75 mL quench solution (0.833N H2SO4). Subsequently, 0.02 mL 
developer (0.417% ammonium molybdate) was added to the mixture at 37
 o
C for 
30 min for the color development. The concentration of phosphate was then 
determined at 700 nm using a spectrophotometer.  
NKA activities from primary cultured rat osteoblasts were determined using a 
Fluorimetric SensoLyte FDP Protein Phosphatase Assay Kit (AnaSpec, Japan) 
according to manufacturer’s instructions. Briefly, 3,6-fluorescein diphosphate 
(FDP) was hydrolyzed by NKA to give rise to the final hydrolytic product, 
fluorescein, which provided a sensitive reading at Ex/Em=485±20/528±20 nm.   
 
2.6 Cell culture and treatment 
Ventricular myocytes were isolated from adult Sprague-Dawley rats, using 
standard enzymatic methods 
159
. Briefly, a central thoracotomy was performed 
after Sprague-Dawely rats (200~250g, male) were anesthetized with 
Ketamine/xylazine (75/10mg/kg) mixture and administrated with Heparin (1000 
IU) by intraperitoneal (i.p.) injection. The heart was quickly excised and perfused 
on a Langendorff system with calcium-free Tyrode’s solution (in mmol/L): 137 
NaCl, 5.4 KCl, 1 MgCl2, 10 HEPES, 10 Glucose, pH 7.4 at 37 °C. After 5 min, 
the perfusate was changed to the Tyrode’s solution containing 1 mg/ml 
collagenase (type I) and 0.28 mg/ml protease (type XIV) and perfused for a 
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further 30 min. Left ventricular tissue was gently minced, filtered, and washed 
three times in calcium containing
 Tyrode’s solution. The cells were allowed to 
stabilize at room temperature for 30 min. All experiments were carried out within 
6 h of cell isolation. . 
AC16 human cardiomyocyte cell line was purchased from Land Biology 
(Guangzhou, China). Cells were maintained in DMEM/F12 medium 
supplemented with 12.5% FBS and 1% penicillin-streptomycin. This basic 
medium was replenished every 3 days. H9C2 rat cardiomyoblast cell line was 
purchased from the American Type Culture Collection (ATCC; Manassas, VA, 
USA) and maintained in DMEM medium supplemented with 10% FBS and 1% 
penicillin-streptomycin..  
Primary osteoblasts were prepared from calvariae of neonatal SD rats by the 
sequential enzymatic digestion method as described previously 
160
. After removal, 
the calcariae were subject to a series of collagenase (Roche, Indianapolis, IN, 
USA) digestions at 37
o
C with shaking under aseptic conditions. Resultant cells 
were pooled and plated in flasks with minimum essential medium alpha (α-MEM, 
Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA). The basic 
medium was also supplemented with 5 mM of β-glycerophosphate, 100 mM of 
L-ascorbic acid, and 0.1 mM of dexamethasone for osteoblast differentiation. Cell 
culture medium was changed every 3 days.   
Primary osteoblasts from adult rat long bones were isolated using the explants 
culture approach as previously described, with modifications 
161
. Briefly, after 
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euthanization, skin, soft connective tissues and periosteum were carefully 
removed from femur and tibia. Epiphyseal cartilage was cleared from disphyses. 
The cleaned bone was cut into small pieces of approximately 5x5 mm3 and 
thoroughly washed with antibiotics. The bone pieces were repeatedly votexed to 
remove blood and bone marrow cells, before they were places into tissue culture 
dish and submerged completely with α-MEM medium supplemented with 10% 
FBS and 1% penicillin-streptomycin. 
MC3T3-E1 osteoblast-like cell line (mouse C57BL/6 calvaria) was purchased 
from the American Type Culture Collection (ATCC; Manassas, VA, USA). Cells 
were maintained in α-MEM medium supplemented with 10% FBS and 1% 
penicillin-streptomycin. This basic medium was replenished every 3 days. To 
induce differentiation, cells were transferred into medium supplemented with 
L-ascorbic acid and β-glycerolphosphate at final concentrations of 50 μg/ml and 5 
mM, respectively (differentiation medium) 
162
.   
In most experiments, cells were pretreated with DR-Ab for 60 min and then 
incubated in freshly prepared medium containing 400 μM H2O2 for 4 h. These 
cells were then used to measure cell viability, apoptosis, PP2A activity or NKA 
activity. For cell differentiation experiments, cells were then washed and cultured 
in fresh differentiation medium. ALP activity and collage content were measured 
after culturing for 5 days. Bone nodule formation was measured with Alizarin red 




2.7 Simulated I/R injury in myocytes 
Freshly isolated rat cardiomyocytes were subjected to ischemia and reperfusion as 
described before 
163
. Briefly, to mimic ischemia, simulated ischemia solution [i.e., 
glucose free Krebs buffer containing 5 mM sodium lactate, 20 mM 
2-deoxy-D-glucose (2-DOG, an inhibitor of glycolysis) 
164
, and 20 mM sodium 
dithionite (Na2S2O4, an oxygen scavenger) 
165
, pH 6.6 was used. The cells were 
subjected to simulated ischemia solution for 10 min and then washed with normal 
culture solution for reperfusion. After 10-min reperfusion, cell viability was 
detected by trypan blue exclusion. After the cells were incubated with 0.4% (w/v) 
Trypan blue dye for 3 min, those that were unstained were termed to be non-blue 
cells. Non-blue cells/total cells were determined in a hemocytometer chamber 
using a light microscope (10×magnification). 200-300 cells in each of 5 cultures 
were tested for each group. 
 
2.8 Measurement of intracellular Ca
2+
 transients  
Cardiomyocytes from different groups were incubated with Fura-2/AM (4μM) in 
Krebs’ buffer for 30min at room temperature for the dye to be loaded into the 
cells. Any unincorporated dye was removed by washing the cells twice with 
Krebs’ buffer with the cells collected by centrifugation (800rpm, 2min). The cells 
were left to stabilize in Krebs’ buffer for another 30min to allow the dye to 
undergo enzymatic de-esterification, trapping the Ca
2+
 indicator in the cytosol. 
The loaded cells were then transferred to the stage of an inverted microscope 
 34 
 
(Nikon) in a superfusion chamber at room temperature. The Fura 2-AM loaded rat 
cardiac myocytes will be measured using the dual-wavelength excitation 
spectrofluorometer (PTI, USA). Fluorescent signals obtained at 340 nm (F340) 
and 380 nm (F380) excitation wavelength will be used to represent [Ca
2+
]i 
changes in myocyte. Cells will be stimulated by suprathreshold (4 ms, 0.2 Hz) 





]i) were generated by adding 10 mM caffeine directly to 
the incubation buffer. Resting Ca
2+ 
level was recorded without any above 
stimulation during ischemia challenge. Fluorescence signals obtained at 340 nm 
(F340) and at 380 nm (F380) excitation wavelengths were recorded and stored in 
a computer for data processing. The F340-to-F380 ratio was used to represent 
[Ca
2+
]i changes in the myocytes. 
 
2.9 Measurement of hemodynamic functions in isolated hearts 
Hemodynamic parameters were measured with a pressure transducer connected to 
a PowerLab system (ADInstruments). An incision was made in the left atrium of 
isolated hearts, and a fluid-filled latex balloon connected to the pressure 
transducer was inserted and positioned in the left ventricular cavity for the 
continuous assessment of cardiodynamic function. The balloon was initially 
inflated to an end-diastolic pressure of 0-10 mmHg, and thereafter the balloon 
volume was held constant. The hearts were perfused at a constant flow rate of 12 
ml/min. Cardiodynamic data were analyzed using a Data Acquisition System 
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(PowerLab System; ADInstruments). Left ventricular end-diastolic pressure 
(LVeDP) was represented by the minimum pressure recorded during diastoles, 
left ventricular developed pressure (LVDP) was calculated as the difference 
between left ventricular systolic pressure and left ventricular diastolic pressure, 
contractility velocity (+dp/dt) was represented by the maximum gradient during 
systoles, and relaxation velocity (-dp/dt) was represented by the minimum 
gradient during diastoles. 
2.10 Model of myocardial infarction (MI) 
Left ventricular myocardial infarction was created in 7-week-old male 
Sprague-Dawley rats. The rat was anesthetized by an intraperitoneal injection of 
ketamine and xylazine (75/10 mg/kg). A 3-cm catheter was inserted into the 
animal's trachea and the animal was ventilated with a Harvard respirator at 78 
strokes per min and tidal volume of 2.15 cm
3
. After thoracotomy at the fourth 
intercostal space, the heart was exteriorized and the left anterior descending 
coronary artery (LAD) was permanently ligated using 6-0 suture. The heart was 
then placed back to normal position and the chest was closed with 3-0 suture. 
Before the animal woke up, extubation was performed together with gentle 
suction of the intubation catheter with a 1 ml syringe to avoid bronchial blockage 
by excessive mucus. The rat was then placed in a recovery cage with a supply of 
oxygen for about 30 min. Analgesia (carprofen at 5 mg/kg/day, s.c.) was 
scheduled for 3 days. Antibiotics (Enrofloxacin at 10 mg/kg/day, i.p.) were also 
given per day for 7 days. About 20% of the animal death occurred during the 
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operation and another 10% occurred within 24 h after the operation. After the first 
24 h, almost all animals survived till the end of the experiments.  
 
2.11 Measurement of hemodynamic functions in vivo post MI surgery 
Heart function was measured 8 weeks after surgery in closed-chest spontaneously 
breathing rats anesthetized with ketamine and xylazine (75/10 mg/kg). Left 
ventricle (LV) catheter (AEC-10C) was placed in the right carotid artery and 
advanced upstream into the LV. LVDP, LVeDP and ±dp/dt were recorded 
continuously with a transducer and Powerlab system connecting with a PC at a 
sampling rate of 2 kHz using Data Acquisition System (PowerLab System; 
ADInstruments) V7.00 software (National Instruments).  
 
2.12 Infarct size measurement 
Infarct size was determined using Evans blue and triphenyltetrazolium chloride 
(TTC) staining. After the hemodynamic measurements had been obtained, the 
hearts were arrested in diastole by a 10% KCl injection, rapidly excised, and 
stained with 0.12% Evans blue to delineate the area at risk (the nonperfused and 
hence unstained myocardium). The heart was then sliced into sections and 
incubated in 1% TTC in PBS for 15 min to define the area of infarction (INF; 
nonviable thus unstained myocardium). Infarct size, ventricle internal diameter 




2.13 Heart parameter measurement 
Hearts were excised, rinsed with saline, and blotted dry upon euthanization of the 
rats. Hearts were weighed, and the right ventricle was removed by dissection 
along its septal insertion. Weights and thickness of LV were measured.  
 
2.14 Isoproterenol-induced heart failure 
Adult male Sprague-Dawley rats at 8 weeks of age were randomly assigned to 
three groups: control, isoproterenol, isoproterenol + DR-Ab. The control rats 
received a single subcutaneous injection of saline. Isoproterenol was dissolved in 
normal saline and subcutaneously injected to the rest of the rats at a dose of 150 
mg/kg 
166
. The animals were kept for 2 weeks for the heart failure to develop for 2 
weeks, followed by an 8-week immunization to produce DR-Ab. 
 
2.15 Preparation of endosomes 
Endosomes were fractioned on a floatation gradient using the technique 
previously described 
167-169
 with some modifications. Briefly, after respective 
treatments, cells were washed with ice-cold phosphate-buffered saline and 
ice-cold homogenization buffer containing 250 mM sucrose and 3 mM imidazole, 
pH7.4. The cells were gently homogenized using a Dounce homogenizer with 
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homogenization buffer supplemented with protease inhibitors, followed by 
centrifugation at 4
o
C, 2000 × g for 10 minutes. The supernatant was adjusted to 
40.6% sucrose and was loaded at the bottom of a centrifuge tube. A 35% sucrose 
solution with 3mM imidazole and 0.5mM EDTA and homogenization buffer was 
added in sequence. The samples were centrifuged for 1.5 hours at 210,000× g in a 
Beckman Ti90 rotor. Endosomes were collected at the homogenization buffer-35% 
sucrose interface. Immunoblots for rab5 or rab7 were carried out to identify the 
endosome fraction. 
 
2.16 Cell viability/cytotoxicity and apoptosis assay 
Cell viability was evaluated with the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method as 
described previously with modification 
170
. Cytotoxicty was measured by lactate 
dehydrogenase (LDH) released into the medium using a commercially available 
kit (Pierce Chemical) following the manual from the manufacturer. To visualize 
nuclear morphology, cells were fixed in 4% paraformaldehyde and stained with 
2.5 μg/ml Hoechst33342 DNA dye. Uniformly stained nuclei were scored as 
healthy viable cells. Condensed or fragmented nuclei were scored as apoptotic. To 
obtain unbiased counting, Petri dishes were coded, and cells were scored blindly 










-ATPase antibody (sc-48345, Santa Cruz Biotechnology) overnight at 
4
o
C. Protein A-Agarose was added and incubated for another 2h the next day. The 
beads were washed 3 times with cell lysis buffer and mixed with 2× loading 
buffer, boiled for 5 min at 99°C and separated in 8% SDS-PAGE. The PP2A 
proteins co-immunoprecipitated was detected with western blots using anti-PP2A 
C subunit antibody (#2038, Cell Signaling). 
 
2.18 Immunofluorescence labeling and protein co-localization  
Cells were fixed in 4% formaldehyde and then permeabilized with 0.1% Triton 
X-100, followed by incubation with mouse anti-NKA antibody (Santa Cruz 
Biotechnology; 1:100 dilutions) or rabbit anti-PP2A antibody (Cell Signaling 
Technology, 1:100 dilutions) overnight at 4°C. After washing for three times with 
PBST (PBS that contained 0.1% Tween-20), cells were incubated with goat 
anti-mouse-Alexa 468 or goat anti-rabbit-Alexa 568 (Invitrogen, 1:400) for 2 hrs 
at room temperature before they were mounted with DAPI containing mounting 
medium (Invitrogen, Carlsbad, CA, USA). Photos were taken using a 
fluorescence microscope (Nikon). 
 
2.19 PP2A activity assay 
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PP2A activities were determined using a Fluorimetric SensoLyte FDP Protein 
Phosphatase Assay Kit (AnaSpec, Japan) according to manufacturer’s instructions. 
Briefly, cells were lysed, and 50μl of the PP2A-containing supernatant was added 
into each well in a black 96-well plate, mixed with 50μl of FDP reaction solution. 
After incubation for 1 h, the reaction was stopped and the fluorescence intensity 
measured at Ex/Em=485/528 nm.  
 
2.20 Biotinylation of cell surface proteins 
Surface proteins were labeled with EZ-Link NHS-SS-biotin (1mg/ml, Pierce 
Chemical Co., Rockford, IL, USA) for 1h as described before 
171
. Cells were then 
rinsed with PBS containing 100 mM glycine thoroughly to quench unreacted 
biotin and then lysed in modified radio-immuno-precipitation assay (RIPA) buffer 
(50 mM Tris-HCl, pH 8; 150 mM NaCl; 1% Nonidet P-40 and 1% sodium 
deoxycholate; 10 μg/ml leupeptin; 100 μg/ml TPCK; and 1 mM PMSF). Proteins 
(150–300 μg) were incubated overnight at 4°C with end-over-end shaking in the 
presence of Streptavidin beads (Pierce Chemical Co.). Beads were thoroughly 
washed, resuspended in 30 μl loading buffer, and analyzed by Western blots. 
 
2.21 Western blotting analysis 
Protein concentrations were determined by the Lowry method. Protein samples 
were separated by 8-12% SDS-PAGE and transferred on to a nitrocellulose 
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membrane (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). After 
blocking at room temperature in 10% milk in TBST buffer (10 mM Tris-HCl, 120 
mM NaCl, and 0.1% Tween 20, pH7.4) for 1 h, the membrane was probed with 
various primary antibodies at 4°C overnight. Membranes were then washed three 
times in TBST buffer, followed by incubation with 1:10,000 dilutions of 
horseradish peroxidase-conjugated anti-rabbit/mouse IgG at room temperature for 
1 h and washed three times in TBST. Visualization was carried out using an 
enhanced chemiluminescence kit (GE Healthcare). The density of the bands on 
Western blots was quantified by densitometry analysis of the scanned blots using 
ImageJ software.  
 
2.22 RT-PCR analysis 
Total RNA was isolated using RNeasy mini kit (Qiagen, Valencia, CA, USA), 
and 1 μg of RNA from each well was reversely transcribed separately into cDNA 
using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). The cDNA 
then was amplified by PCR with Dream Taq Green PCR Master Mix (Thermo 
Scientific, Singapore) in a total volume of 20 μl, in the presence of 10pM of 
specific primers. PCR products were analyzed by 1% agarose gel electrophoresis 
and visualized by the Multigenius Bioimaging system (Syngene, UK). To assess 
the level of gene transcription, the density of each band was normalized to the 
value of its corresponding housekeeping gene, GAPDH or β-actin. The primers 
used in the present study include  
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Runx2 (F: 5′-CTCAGTGATTTAGGGCGCATT-3′ 
R:5′-AGGGGTAAGACTGGTCATAGG-3’), ALP  
(F: 5′-CCATGGTAGATTACGCTCACA-3′  
R: 5′-ATGGAGGATTCCAGATACAGG-3′), BSP  
(F: 5′-TACCGAGCTTATGAGGATGAA-3′  
R: 5′-GCATTTGCGGAAATCACTCTG-3′), RANK  
(F: 5′-AGATGTGGTCTGCAGCTCTTCCAT-3′  
R: 5′-ACACACTTCTTGCTGACTGGAGGT-3′), RANKL  
(F: 5’-TGTACTTTCGAGCGCAGATG-3’ 
R: 5’-CCCACAATGTGTTGCAGTTC-3’), Actin 
(F: 5′-GGTCGTACCACAGGCATTGTGATG-3′  
R: 5′-GGAGAGCATAGCCCTCGTAGATGG-3′). The primers for NKA mRNA 
detection were from Santa Cruz Biotechnology. 
 
2.23 Collagen content assay 
Extracellular soluble collagen content in medium was measured using a Sircol 
Collagen Assay kit (Biocolor Ltd., UK) according to manufacturer’s instruction. 
This Sircol collagen assay is a quantitative dye-binding method commonly 
applied in the analysis of collagens extracted from mammalian tissues and cells in 




2.24 Measurement of extracellular matrix (ECM) calcium deposition 
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Staining with Alizarin red S is used to visualize bone nodule formation and 
calcium deposition of osteoblasts cultured in vitro 
173
. Since the dye chelates 
ECM calcium to form a complex, heavy reddish staining of the Alizarin red S is 
proportional to area of mineralized ECM. At harvest, both MC3T3-E1 and 
primary cultured osteoblastic cells were fixed and stained using Alizarin red S for 
calcium precipitation to be visualized under light microscopy. Only data from 
primary cultured cells are shown in results. 
 
2.25 In vitro GST pull down assay 
pGEX-6p-1 plasmids containing 6 different intracellular domains of the NKA 
α1-sununit sequences were kindly provided by Dr Emilia Lecuona (Feinberg 
School of Medicine, Northwestern University, Chicago) as a gift. GST fusion 
proteins of the 6 different intracellular domains of the NKA α1-sununit were 
expressed in BL21 bacterial cells and purified by glutathione-Sepharose 4B 
(Amersham Biosciences). GST fusion proteins and GST bound to 
glutathione-Sepharose beads (0.5μg) were incubated with osteoblast cell lysates 
overnight at 4
o
C. The beads were washed 3 times with cell lysis buffer and, mixed 
with 2× loading buffer and separated in 8% SDS-PAGE. The proteins were 
detected by Western blots. 
 
2.26 Ovariectomy-induced rat osteoporosis model 
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Three-month-old female Sprague-Dawley rats were divided into three groups: 
sham surgery followed by PBS vehicle treatment (sham), ovariectomy followed 
by PBS treatment (OVX), ovariectomy followed by DR-Ab treatment (OVX-DR). 
Rat ovariectomy surgery model was performed by single midline dorsal skin 
incision. Animals were allowed to develop osteoporosis for at least 12 weeks. In 
OVX-DR group, animals were immunized with DR peptide starting 4 weeks after 
surgery, when OVX animals had developed osteoporosis.  
 
2.27 Biochemical analysis 
Rats were fasted overnight before morning blood collection. Whole blood (0.2ml) 
was collected from tail vein to obtain serum. Serum osteocalcin was measured 
with Rat-MID
TM
 osteocalcin EIA kit (IDS, Fountain Hills, AZ, USA). The serum 
C-telopeptide of type I collagen (CTX-1) was measured by RatLaps
TM
 EIA kit 
(IDS, Fountain Hills, AZ, USA).  
 
2.28 Bone section preparation 
After euthanasia, right femurs were collected for immunohistochemical studies. 
They were fixed in 4% paraformaldehyde (pH7.4) for 3 days before 
decalcification in 16% EDTA (pH7.4) for 21 days. Following decalcification, 
femurs were dehydrated in alcohol and embedded in paraffin. Five-micro-thick 
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sections of the femurs were cut longitudinally and used for detection of NKA and 
alkaline phosphatase by immunohistochemistry.  
 
2.29 Immunohistochemical processing 
Immunostaining was performed on paraffin-embedded sections using a mouse 
anti-NKA antibody. A mouse ABC staining kit (Santa Cruz, CA, USA) was used 
according to manufacturer’s instructions to amplify the signal of NKA. Sections 
were counterstained with hematoxylin. Immunohistochemical reactions were 
controlled to evaluate the specificity of the labels. Hematoxylin and eosin staining 
were performed as a reference of the cytoarchitecture of the tissue. 
 
2.30 In vivo and ex vivo micro-computed tomography (µCT) 
In vivo µCT scanning was performed during the development of osteoporosis with 
Quantum FX µCT pre-clinical in vivo imaging system (Caliper Life Sciences, 
Hopkinton, MA). After the animals were euthanized, metaphysis region of 
proximal tibia was scanned ex vivo in an upright position with a source of object 
distance (SOD) of 121 mm and a source to camera distance (SID) of 161 mm 
using a Skyscan 1076 micro X-ray computed tomography (µCT) scanner 
(Skyscan, Belgium). A 3.6 mm-thick volume of interest (VOI, 200ct slices) was 
selected 1 mm below the distal growth plate. The resultant grayscale images 
obtained had an isotropic voxel size of 17.75 µm from cone-bone reconstruction 
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(100 kV, 100 µA, using a 1.0 mm Al filter and averaged 3 times). A 
semi-automated contouring method was employed to select trabecular from 
cortical bone. The grayscale images were segmented using a global threshold of 
15.0% of the maximal grayscale value 
174
. Direct 3D measurement methods were 
used to assess trabecular bone volume ratio (BV/TV), bone surface to volume 
ratio (BS/BV), trabecular separation (Tb.Sp), trabecular number (Tb.N), 
trabecular thickness (Tb.Th), structural model index (SMI), mean bone mineral 
density (mBMD) and trabecular BMD (Tb.BMD) for the same VOI using the CT 
Analyser program (Phil Salmon, Skyscan). 3D visualization of the VOI using 
adaptive rendering algorithm was done with the ANT software (Skyscan, 
Belgium). 
 
2.31 Mechanical testing 
Immediately after µCT, each tibia was placed on a specifically developed 
three-point bending and breaking test device as previously established 
175
. A 
micro-testing machine (Instron 5848, Norwood, MA, USA) with a measuring 
range from 2 N to 500 N at a precision of 0.2% of the load was used. The 
movable base was placed to ensure the distance between the proximal end of the 
tibia (without epiphysis) and the center of the loading stamp was 3 mm 
throughout the test. A loading speed of 0.05 mm/s was applied to the tibia until 
fracture. The experiment was programmed to stop in case of a strength drop 
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of >20N or a linear displacement of >2mm to avoid shattering the femur 
specimens. Maximum load (Fmax) was recorded using “Merlin” software.  
 
2.32 Generation of plasmids containing mutated NKA 
The mutated plasmids pIRES_DsRed_rNKA-DR_cMyc were created with 
Phusion Site-Directed Mutagenesis Kit following the manufacturer instruction 
with modification. Briefly, plasmid pIRES_DsRed_rNKA was amplified by PCR 
with primers which can replace the DR region with SpeI cutting site and c-Myc 
coding sequence shown below. 
Spel_NKA_R: ATA ACTAGT CTCCACATCATTGATCCAGCG 
SpeI_cMyc_NKA_F:ATAACTAGTATGGAACAAAAACTTATTTCTGAAGA
AGATCTGAAGATTGTGGAGTTCACCTGCC  
Spel_NKA_R2: ATA ACTAGT ATTGATCCAGCGGTCATCCC  
The PCR products were digested with SpeI and ligated and transformed into 
DH5α cells. The clones were screened by direct sequencing.  
 
2.33 NKA knockdown by siRNA transfection 
RNA interference was used to silence the expression of NKA in MC3T3-E1 cells. 
Cells were plated in six-well plates and cultured in antibiotic-free medium 
overnight before they were transfected with siRNAs (80 pmol/well) using 
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Lipofectamine 2000 according to the manufacturer’s instructions. Cells were 
cultured for at least 3 days before various assays were carried out. 
 
2.34 Single cardiomyocyte contraction measurement  
Rod-shaped cardiomyocyte with clear striation were chosen in this experiment. 
Contraction amplitude was recorded through a ×40 objective lens (Nikon) and 
transmitted to a CCD black and white video camera (NL-2332; National 
Electronic, Canada). The output from the camera was displayed on a monitor 
(National Electronic). The edge of the cardiomyocyte was identified using a video 
motion edge detector (VED-105; Crescent Electronics, Canada). The darkness 
contrast at the edge of the myocytes provided a marker for measurement of the 
amplitude of contraction. The cells were left untreated for at least 10 minutes to 
allow cells to stabilize before the treatment began.   
 
2.35 ex vivo global and regional heart ischemia and reperfusion 
Male Spragure-Dawley rats were anesthetized with ketamine/xylazine and 
heparinised. The heart was rapidly excised and connected to a Langendorff 
perfusion apparatus through the aorta and perfused with oxygenated Krebs buffer 
containing (in mmol/L): 120 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 
MgSO4, 1.2 MgSO4, 1.25 CaCl2, and 11 glucose, for 10 minutes to stabilize the 
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heart contraction. The heart was then perfused with Krebs buffer, normal serum 
antibody, or DR-Ab (2 μM) for 1 hour. In global ischemia and reperfusion model, 
the heart was subjected to 30 min of no-flow global ischemia and 90 min of 
reperfusion with oxygenated Krebs buffer. In regional ischemia and reperfusion 
model, the left anterior descending (LAD) artery was ligated to induce regional 
ischemia for 30 min, followed by 90 minutes of reperfusion. Cardiac function was 
evaluated by measuring hemodynamic parameters including LVDP (left 
ventricular developed pressure), LVeDP (left ventricular end diastolic pressure), 
and ±dp/dt (rate of left ventricle pressure rise or fall), using a pressure transducer 
connected to a water-filled balloon inserted into the left ventricle. All data were 
recorded using Powerlab system (ADInstruments).  
 
2.36 Soluble receptor activator of nuclear factor κ-B ligand (RANKL) 
measurement 
RANKL released into cell supernatant was measured using a RANKL mouse 
ELISA kit (Abcam ab100749) following the manufacturer’s instructions. Briefly, 
RANKL standards and samples were added into a 96-well plate coated with 
anti-RANKL capture antibody and incubated overnight at 4
o
C. Biotinylated 
RANKL detection antibody was then added and incubated for 1 hr at room 
temperature, followed by 1 hr incubation with HRP-Streptavidin solution. TMB 
substrate reagent was added to each well for the coloring reaction to take place for 
30 min at room temperature in the dark. The reaction was stopped by adding stop 
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solution. Absorbance of the wells at 450 nm was read and used to calculate the 
RANKL concentration based on 4-parameter logistic regression fit curve.  
 
2.37 Statistical analysis  
Values are presented as Means±SEM. We used one-way analysis of variance 
followed by Bonferroni or Tukey’s Honestly Significant Difference (HSD) test to 





















































Part I DR-Ab protects cardiomyocytes from oxidative injury and produces 
therapeutic effect in heart failure rats.  
 
3.1 DR-Ab binds to and activates NKA 





which resides in the extracellular L7/8 loop in NKA α-subunit (Fig. 4A). After 
immunization procedures in rats, the titer of antibody was detected with ELISA 
against DR peptides. Both immunized sera and purified DR-Ab showed strong 
reaction against DR peptide, as shown by the significantly higher absorbance 
readings than the control even as diluted as 1:12800 and 1:6400, respectively (Fig. 
4B). To test if DR-Ab could recognize NKA, the sodium pump was purified from 
both rat and mouse kidney medulla, subjected to SDS-PAGE, and probed with 
both DR-Ab and commercially available NKA α antibody (H-3). As shown in 
Figure 4C, both DR-Ab (upper panel) and H-3 antibody (lower panel) detected 
the NKA of rat and mouse origins. The effect of DR-Ab on NKA activity was 
also determined biochemically using purified rat NKA. Incubation with various 




























Figure 4. DR-Ab binds to and activates NKA from rat and mouse tissues. 
(A) Schematic illustration showing the localization of DR region in the α1 
subunit and the binding of DR-Ab. (B) DR-Ab dilution factor before and after 
purification for DR-Ab. Negative control: normal serum antibody. (C) NKA of 
both rat and mouse origins was detected with either H-3 or DR-Ab. (D) DR-Ab 
concentration-dependently stimulates NKA activity in purified NKA from 
kidney. (The concentration of DR-Ab was calculated based on protein 
concentration and the molecular weight of IgG (~150kD) and expressed in 
μM) Mean±SEM. n=5-6. Mean±SEM **p<0.01, ***p<0.001 vs control 




3.2 DR-Ab protects cardiomyocytes from oxidative injury 
3.2.1 DR-Ab protects against ROS-induced cytotoxicity in AC16 cells 
As oxidative stress underlies many adverse events in coronary heart diseases, 
H2O2, a ROS donor, was used to study the effect of DR-Ab on cellular response to 
high ROS environment. Exogenous H2O2 concentration-dependently led to cell 
injury in AC16 human cardiomyocyte cell line (Figure 5A), and pretreatment with 
DR-Ab (2 μM, 60 min) significantly attenuated the injury caused by 400-1000 
μM of H2O2 (Figure 5B). The concentration of H2O2 in most of the following 
experiments was therefore chosen at 400 μM if not otherwise indicated. The 
time-course analysis showed that the protective effect lasted for at least 24 hours 
(Figure 5C). Antibody purified from rat normal serum (NS) was used as a control 
to eliminate the possibility that the protection was a result of other antibodies than 
DR-Ab contained in the serum. Morphological changes of the H2O2-treated cells, 
as characterized by shrinkage and detachment from the culture dish, were largely 
inhibited to a minimal level in cells incubated with DR-Ab (Figure 5D). Cellular 
apoptosis was quantified using Hoechst 33342 staining. As shown in Figure 5E, 
H2O2 induced apoptosis in nearly 20% of the cells, as reflected by the condensed 
and fragmented nuclei. In contrast, much reduced apoptotic activity was shown in 
DR-Ab pretreated cells. The necrotic cytotoxicity was measured by lactate 
dehydrogenase (LDH) release assay, in which LDH level was found elevated in 
culture medium of H2O2-treated cells, while incubation with DR-Ab significantly 





























3.2.2 DR-Ab protects isolated rat cardiomyocytes and hearts against 
ischemia and reperfusion injury  
Isolated adult rat ventricular myocytes are highly susceptible to damage during 
the enzymatic digestion and cannot be cultured for extended periods. Indeed, the 
number of viable myocytes, as measured by Trypan Blue exclusion assay, showed 
a downward trend over 24 hours of culturing. Myocytes incubated with DR-Ab 
showed consistent higher viability at various time points (0, 3, 6, 12 or 24 hr) (Fig. 
6A). As ischemia and reperfusion injury is very often implicated in coronary heart 
diseases and large amount of ROS generated during the process contributes to 
massive myocyte death, the protective effect of DR-Ab was assessed in isolated 
rat cardiomyocytes and hearts subjected to ischemia and reperfusion. Freshly 
prepared ventricular myocytes were treated with simulated ischemic buffer for 10 
minutes, followed by change of medium to normal culture medium for another 10 
Figure 5. Protective effect of DR-Ab against ROS injury in AC16 cells. 
(A) Cytotoxicity induced by exposure to increasing concentrations of H2O2 for 
4 hours, as measured by MTT. n=8; (B) Protection of DR-Ab by 1 hr of 
pre-incubation prior to H2O2 inhibits cell death. n=8; (C) The protective effect 
lasted for at least 24 hr. n=4; (D) Morphological changes (shrinking and 
detachment) in H2O2–treated cells was absent in DR-Ab pretreated cells. n=5; 
(E) DR-Ab reduced apoptosis induced by overnight incubation with 100 μM 
H2O2, as measured by the condensed and bright nuclei in Hoechst33342 
staining. n=3; (F) H2O2 increased LDH level in culture media and DR-Ab 
pretreatment reduces it. n=3. Mean±SEM. *p<0.05, **p<0.01, ***p<0.001 vs 
control, #p<0.05, ##p<0.01, ###p<0.001 vs corresponding H2O2 treatment 




minutes to mimic reperfusion. The number of living cells was counted and it was 
found that DR-Ab significantly improved the cell survival rate against 
ischemia/reperfusion injury (Fig. 6B). Next, cardioprotection conferred by DR-Ab 
was studied in ischemic/reperfusion caused heart injury. Isolated rat heart were 
perfused with Krebs buffer (Vehicle), normal serum antibody (2 µM, Control) or 
DR-Ab (2 µM) for 1 hour before ligation of the left anterior descending (LAD) 
artery to induce regional ischemia for 30 minutes. This was followed by 90 
minutes of reperfusion, at the end of which Evans blue was perfused into the aorta 
and coronary arteries. The areas stained blue in the ventricle sections below the 
ligature represent areas not at infarction risk. Subsequently, TTC stained area 
(stained in red) indicates ischemic but viable tissue, leaving the infarct area pale 
white. The ischemia and reperfusion protocol resulted in significant areas of 
infarction, as indicated by the pale myocardium. Perfusion with DR-Ab reduced 










3.2.3 Membrane NKA abundance is reduced under oxidative stress  
A body of growing evidence indicates NKA as a target protein of ROS, which 
downregulate NKA activity and expression 
176-178
. It is, therefore, of our interest to 
Figure 6. Protective effect of DR-Ab against ischemia reperfusion injury in 
isolated cardiomyocytes and hearts. (A) Time course study of the protective 
effects of DR-Ab in isolated rat cardiomyocytes without any treatment. DR-Ab 
increased cell viability at 3, 6, 12, and 24 hr. n=10; (B) Protective effect of 
DR-Ab in rat cardiomyocytes against simulated ischemia and reperfusion (I/R) 
injury. DR-Ab pretreatment for 1 hr improved post I/R cell survival. n=3; (C) 
Upper panel: representative photo showing the infarct size, as visualized by 
Evans blue and TTC double staining, after I/R protocol. Lower panel: group 
analysis of the infarct size quantification. Perfusion with DR-Ab reduced infarct 
size in hearts subjected to regional ischemia (30 min) and reperfusion (90 min). 
n=4-6. Mean±SEM. *p<0.05, ***p<0.001 vs control, #p<0.05 vs NS+I/R 
treatment group. NS: Rat normal serum antibody, as negative control. 
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study if NKA function is compromised in cardiomyocytes under high ROS 
environment. In AC16 cells the activity of NKA appeared significantly suppressed 
in the presence of H2O2 but was restored to a large extent by DR-Ab treatment 
(Figure 7A). In order to understand how H2O2 suppressed NKA activity, the 
surface density of the enzyme we examined in the presence of H2O2. Biotin 
labeled cell surface NKA was reduced by close to 40% in response to 200 µM of 
H2O2 for 1 hour (Figure 7B). Cells pretreated with DR-Ab showed no such 
reduction (Figure 7B). Isolated rat cardiomyocytes were labeled, without 
membrane permeabilization, with commercially available antibody against the 
extracellular region of NKA after they were subjected to ischemic buffer (15 min) 
and reperfusion (15 min) with culture medium. Immunofluorescence under 
confocal microscope revealed loss of NKA on plasma membrane similar to the 
results found with H2O2-treated AC16 cells. The effect of simulated ischemia and 
reperfusion paralleled that of H2O2 in reducing the membrane density of NKA. 
The decrease in cell surface density of NKA was inhibited by incubation with 




























Figure 7. Effect of H2O2 and ischemia/reperfusion on plasma membrane 
NKA activity and abundance. (A) AC16 cells treated with 100 μM of H2O2 
for 1 hr showed reduced NKA activity. Pretreatment with DR-Ab for 1 hr 
maintained NKA activity at a significantly higher level. n=4; (B) Upper panel: 
representative western blot showing the plasma membrane NKA density in AC 
16 cells treated with 100 μM of H2O2 for 1 hr. Lower panel: group analysis of 
the aforesaid results. DR-Ab treatment reversed the H2O2-induced membrane 
NKA reduction. n=6; (C) Representative confocal immunostaining images 
showing reduced NKA density on plasma membrane of isolated rat 
cardiomyocytes subjected to ischemia (15 min) and reperfusion (15 min). 
Membrane NKA abundance was maintained in cells pre-incubated with DR-Ab. 
n=5. Mean±SEM. *p<0.05, **p<0.01 vs control, #p<0.05, ###p<0.001 vs NS+ 





3.2.4 Endocytosis mediates the reduction of NKA on plasma membrane  
One of the mechanisms regulating the NKA activity and membrane abundance is 
regulated endocytosis and recycling 
179
. It has been proposed that acute ROS 
exposure triggers NKA endocytosis without affecting the total level of NKA 
protein 
180
. To define the mechanism underlying the loss of membrane NKA in 
our findings, endosomes were isolated and the contents studied using western blot. 
As shown in Figure 8A, after being exposed to 200 µM of H2O2 for 1 hour, NKA 
was enriched by approximately 50% in endosomes extracted from AC16 cells, 
and incubation with DR-Ab prevented such rise in concentration of endosomal 
NKA, suggesting that the reduction of cell surface NKA was via its endocytosis, 
which could be inhibited by DR-Ab. To further confirm this finding, cells from 
different treatment groups were fixed, permeabilized, and probed with antibodies 
against NKA and an early endosome marker, EEA-1, to track the whereabouts of 
NKA removed from plasma membrane. The co-localization of 
immunofluorescence signals of NKA and EEA-1, upon H2O2 administration, 
confirmed that endocytosis was responsible for oxidative stress-induced loss of 








Figure 8. Endocytosis of NKA is responsible for reduced NKA on plasma 
membrane. (A) Left panel: Representative western blot showing the content of 
endosomes isolated from cells of different treatment groups. Incubation with 
100 µM H2O2 for 1 hr induced enrichment of NKA in the endosomes. Right 
panel: Group analysis of the endosomal NKA level. n=4; (B) Representative 
immunofluorescence staining showing the co-localization of NKA (Green) with 
endosome marker EEA1 (Red) in AC16 cells treated with 100 µM H2O2 for 1 
hr. n=11. Mean±SEM. *p<0.05 vs control, #p<0.05 vs H2O2 treatment group. 




3.2.5 Protein phosphatase 2A (PP2A) suppression mediates NKA 
endocytosis 
Several reports have documented the phosphorylation of certain serine residues on 
NKA α subunit as an essential event that triggers the endocytosis of the sodium 
pump 
167,169,181-183
. Here, the level of phosphorylated Ser18 was evaluated using 
McK1 antibody, which recognizes the unphosphorylated α1 subunit at Ser18. As 
shown in Figure 9A, H2O2 induced phosphorylation of Ser18, which was reversed 
by DR-Ab. It has been reported that PKCζ and PP2A are responsible for the 
phosphorylation state of NKA 
171,183-186
, thus regulating the removal and insertion 
of NKA within the plasma membrane. To understand whether the declined 
phosphorylation by DR-Ab was a result of inhibited kinase or enhanced 
phosphatase activity, the activity of PKCζ in H2O2-treated AC16 cells was first 
examined. Increased PKCζ translocation from cytosolic to membrane fraction 
occurred 30 minutes after H2O2 treatment and DR-Ab failed to have any impact 
on PKCζ activation (Figure 9B). On the other hand, DR-Ab mitigated the H2O2 
suppression on PP2A activity (Figure 9C), suggesting the involvement of PP2A in 
the regulation of NKA phosphorylation by DR-Ab. PP2A has been reported to 
directly interact with NKA 
187
. Such direct association of NKA and PP2A was 
verified using co-immunoprecipitation. Lysate of AC16 cells were incubated with 
anti-NKA antibody, followed by Protein A-Agarose. The amount of PP2A 
precipitated was detected with western blots with NKA as a loading control. As 
shown in Figure 9D, H2O2 evidently reduced the affinity of the two enzymes to 







Figure 9. Protein phosphatase 2A (PP2A) is involved in H2O2-induced NKA 
endocytosis. (A) Upper panel: representative western blot of McK1 showing the 
unphosphorylated NKA at Ser18 in H9C2 rat myoblast cell line exposed to 
100µM H2O2 for 30 min. Lower panel: group analysis of the NKA 
phosphorylation state under different treatment groups. n=3; (B) Upper panel: 
representative western blot of PKCζ in the membrane and cytosolic fractions of 
cell lysate. Lower panel: group analysis of the PKCζ translocation under 
different treatment groups. n=3; (C) Suppression and restoration of PP2A 
activity by H2O2 and DR-Ab in AC16 cells. n=3; (D) Co-immunoprecipitation 
analysis showing the direct interaction of PP2A and NKA. IgG: normal mouse 
IgG as negative control. Input: total cell lysate as positive control. Mean±SEM. 
*p<0.05, **p<0.01, ***p<0.001 vs control, #p<0.05, ##p<0.01 vs H2O2 




3.2.6 Stabilization of membrane NKA by PP2A activation mediates the 
protective effect of DR-Ab against ROS  
To test if activation of PP2A by DR-Ab underlies the protective effect, PP2A was 
blocked using its specific inhibitors, okadaic acid (10 nM) and cantharidin (1 µM). 
As measured by MTT assay, the protective effect induced by DR-Ab against H2O2 
was abolished with the application of either okadaic acid or cantharidin, 
suggesting the essential role of PP2A in the antioxidative protection of DR-Ab 
(Fig 10A). Also, neither okadaic acid nor cantharidin alone induced cytotoxicity 
(Fig 10A). To elucidate the correlation between NKA and cell vulnerability 
against oxidative stress, siRNA transfection was employed to knock down the 
translation of NKA. Reduced NKA expression rendered AC16 cells more 
vulnerable to oxidative damage, as well as abolished the protective effect of 
DR-Ab (Fig 10B), highlighting the importance of NKA in the cellular defense 
machinery under high ROS conditions. To eliminate the possibility that our 
observation with DR-Ab was caused by its non-specific binding, HEK293 cells 
were transfected with plasmid containing NKA α1 within which the DR-region 
was substituted by C-myc sequence, and the effect of DR-Ab on preserving 
membrane NKA concentration was examined under oxidative stress. As shown in 
Figure 10C, consistent with the findings in cardiomyocytes, control and WT 
plasmid-transfected HEK293 cells displayed reduced NKA on plasma membrane 
when challenged by H2O2, and DR-Ab was able to reverse the decline. On the 
contrary, incubation with DR-Ab failed to have an impact on NKA membrane 
abundance in cells expressing NKA with its DR-region replace by c-Myc, 
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confirming that binding to the DR-region by DR-Ab is necessary for preventing 





























Figure 10. Stabilization of NKA on plasma membrane via PP2A activation 
mediates protective effect of DR-Ab. (A) Left: Effect of PP2A inhibitors, 
okadaic acid (OK, 10nM) and cantharidin (Cant, 1µM), on the DR-Ab conferred 
antioxidative protection. n=8; Right: Effect of OK (10nM) or Cant (1 µM) on cell 
viability. n=16; (B) Left: RT-PCR resulting showing the effect of siRNA on NKA 
transcription. Right: Effect of NKA silencing by siRNA on cell viability under 
oxidative stress. n=3; (C) Representative immunofluorescence images showing the 
membrane abundance of NKA in HEK293 cells transfected with plasmids 
containing WT or modified NKA, which had the DR-region replaced by C-myc. 
n=6. Mean±SEM. ***p<0.001 vs control, ###p<0.001 vs H2O2 group, ^^^p<0.001 




3.3 DR-Ab improves cardiac function in failing hearts  
3.3.1 DR-Ab induces positive inotropy in cardiomycoytes 
The effect of DR-Ab on cardiomyocyte contractility was studied using freshly 
isolated rat cardiomyocytes. Over a period of 30 minutes upon introduction of 
DR-Ab, rat cardiomyocytes showed a gradual yet significant augmentation in the 
contraction magnitude, as compared to the cells treated with normal serum 
antibody (NS) (Fig. 11A). After the contraction amplitude stabilized, an 
approximately 20% increment was found in DR-Ab treated cardiomyocytes 
relative to those treated with NS antibody (Fig. 11B). 
 
3.3.2 DR-Ab increases intracellular Ca2+ transients in cardiomyocytes 
Increased intracellular Ca
2+
 concentration is responsible for most positive 
inotropic agents. Since incubation with DR-Ab resulted in augmented contraction 
amplitude, its effect in intracellular Ca
2+
 concentrations was then studied. As 
shown in Figure 12A, similar to the time course of the positive inotropic effect, 
DR-Ab elevated electrically-induced Ca
2+
 transients in rat cardiomyocyte over a 
period of 30 minutes. Group analysis showed that DR-Ab consistently incurred 
approximately 10% increment in intracellular Ca
2+
 concentration, as measured by 
Fura-2AM fluorescent calcium indicator (Fig. 12B). These data suggest that 







Figure 11. Effect of DR-Ab on the myocyte contractility. (A) 
Representative time course tracing of electrical stimuli-induced 
contraction of rat cardiomyocytes showing the positive inotropic effect 
of DR-Ab. (B) Representative tracing (upper panel) and group analysis 
(lower panel) showing the contraction of mouse cardiomyocytes treated 
with DR-Ab (2μM, 30 min). n=12. Mean±SEM. *p<0.05 vs NS, NS: 







Figure 12. Effect of DR-Ab on the intracellular Ca
2+
 transients. (A) 
Representative time course tracing of electrical stimuli-induced intracellular 
Ca
2+
 transients in rat cardiomyocytes showing that DR-Ab increased 
intracellular Ca
2+
 concentration. (B) Representative tracing (upper panel) and 
group analysis (lower panel) showing the amplitude of Ca
2+
 fluctuations in rat 
cardiomyocytes treated with DR-Ab (2μM, 30 min). n=12. Mean±SEM. 
*p<0.05 vs NS, NS: normal serum antibody. 
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3.3.3 DR-Ab improves cardiac function in isolated rat hearts subjected 
to ischemia and reperfusion injury 
Cardiac function was evaluated by measuring hemodynamic parameters including 
LVDP (left ventricular developed pressure), LVeDP (left ventricular end diastolic 
pressure), and ±dp/dt (rate of left ventricle pressure rise or fall). Freshly isolated 
rat hearts were perfused with oxygenated Krebs buffer for 10 minutes for their 
contraction to stabilize before they were perfused with Krebs buffer, normal 
serum (NS) antibody, or DR-Ab (2 μM) for 1 hour. Hearts were then subjected to 
global ischemia for 30 min, followed by reperfusion with oxygenated Krebs 
buffer for 90 min. Hemodynamics were measured during the entire experiment 
course. As shown in Figure 13A-D, relative to hearts perfused with Krebs and NS 
antibody, hearts perfused with DR-Ab for 1 hour prior to I/R protocol displayed 
significantly increased LVDP (Figure 13A) and the absolute values of ±dp/dt 
(Figure 13C&D), but decreased LVeDP (Figure 13B) during reperfusion, 
suggesting its beneficial effect in preserving cardiac function following ischemia 
















Figure 13. Preservation of cardiac function by DR-Ab following ischemia 
reperfusion injury in isolated hearts. (A&B) Hearts perfused with DR-Ab 
(2μM) for 1 hr showed significantly higher LVDP (A) and lower LVeDP (B) 
than control hearts after ischemia (30min) and reperfusion (90min); (C&D) 
Hearts perfused with DR-Ab (2μM) for 1 hr resumed with higher ventricular 
contraction (C) and relaxation (D) velocity than control hearts after ischemia 
(30min) and reperfusion (90min), as indicated by the increased absolute values 
of ±dp/dt. n=5-7. Mean±SEM. *p<0.05, vs control (normal serum antibody).  
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3.3.4 Establishment of a heart failure model by myocardial infarction 
To study the effect of DR-Ab in failing hearts, a myocardial infarction-induced 
heart failure rat model was first established. Myocardial infarction (MI) was 
surgically induced by ligation of the left anterior descending (LAD) artery. The 
resultant contractile injury led to heart failure. Cardiac infarct size, hemodynamic 
parameters, and left ventricle geometry were determined 2 months after the 
surgery. As shown in Figure 14 A&B, the infarct size in MI rats was about 20% of 
total size of heart. Ventricle internal diameter was significantly higher (Fig. 14C), 
whereas anterior wall was significantly thinner in the heart failure model (Fig. 
14D), relative to those of the sham operated animals. Cardiac hemodynamics 
showed that the absolute values of LVDP and ±dp/dt were significantly reduced 
while LVeDP was significantly increased in the heart failure model rats (Fig. 














Figure 14. Establishment of heart failure rat model by myocardial 
infarction. (A&B) Representative myocardial sections (A) in sham (Left 
panel) and myocardial infarction (Right panel) rats and group analysis (B) 
showing the infarct size in heart failure model. (C&D) Significantly increased 
left ventricle internal diameter (C) and decreased left ventricular anterior wall 
thickness (D) in myocardial infarction-induced heart failure rats, n=21. (E-H) 
Cardiac hemodynamic parameters of myocardial infarction model rats 
compared with sham rats, n=21. Mean±SEM. *p<0.05 vs sham.  
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3.3.5 DR-Ab improves cardiac function in heart failure model 
Next, the study was continued with the therapeutic effect of DR-Ab on the 
impaired contractile function in the heart failure rats. Upon the successful 
establishment of the heart failure model, cardiac hemodynamic parameters of the 
MI rats were measured. Animals were allowed 30 minutes for the readings to 
stabilize, prior to the intravenous administration of saline, normal rat antibody 
(control), or DR-Ab (0.005 µmol). DR-Ab significantly increased LVDP starting 
from 40 min after infusion (Fig. 15A), but decreased LVeDP 80 min after infusion 
(Fig. 15B), as compared with the saline or normal antibody treated hearts. The 
rate at which ventricular pressure rises or falls (±dp/dt), which is a reasonable 
index of the velocity or myocardial contraction or relaxation, showed substantial 
rise in DR-Ab infused rat in comparison with the control (Fig. 15C&D). The 
maximum response was observed 1h after treatment. These data suggest that 












Figure 15. Effect of DR-Ab on cardiac contractile function in heart failure 
rats. (A&B) Injection of DR-Ab (0.005µmol) significantly increased LVDP 
(A), and lowered LVeDP (B), 40 min and 80 min, respectively, after the 
injection, as compared with the saline or normal serum antibody infused rats. 
(C&D) Injection of DR-Ab significantly increased the absolute value of left 
ventricular +dp/dt (C) and –dp/dt (D) 40 min after the injection, as compared 
with the saline or normal serum antibody infused rats. n=21. Mean±SEM. 
*p<0.05 vs control.  
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3.3.6 DR-Ab alleviates cardiac hypertrophy and reverses NKA reduction 
in failing myocardium 
The NKA expression was reduced in cardiomyocytes subjected to oxidative stress 
and I/R injury and DR-Ab maintained its cell surface density. To investigate 
whether such observations in cellular models reflect the in vivo changes in heart 
failure, the NKA level was assessed in the myocardium of the 
isoproterenol-induced heart failure specimens. Heart failure was induced by toxic 
cardiomyopathy, a widely used experimental model for studying chronic heart 
failure 
190
. Administration of excessive amount of catecholamines, such as 
isoproterenol (ISO) results in massive myocardial damage and extensive fibrosis 
191
, and a subsequent infarct-like myocardial necrosis 
192
 with reduced functional 
capacity of the heart 
193-194
. ISO-treated rats show necrotic myocardium death and 
progressive enlargement of the LV cavity out of proportion to mass, similar to 
patients with discrete myocardial infarction 
195-196
. 
Following the single dose of 150 mg/kg ISO injection (2 weeks) and 
immunization with DR-peptide (8 weeks), the animals with high DR-Ab 
(titer>6400) were sacrificed and the somatic and organ weights were measured to 
evaluate the ISO-induced heart hypertrophy. No significant difference in body 
weight was found among different groups (Fig. 16A). The heart and left ventricle 
weights of ISO-treated rats were significantly increased, as compared with the 
control group (Fig. 16B&D). ISO-treated rats with circulating DR-Ab showed 
decreased heart and left ventricle weight relative to ISO group (Fig. 16B&D). 
When normalized with body weight, ISO-induced hypertrophy was still evident 
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(Fig. 16C&E). Circulating DR-Ab alleviated the ISO-induced hypertrophy, as 
reflected by the decreased ratio of heart/left ventricle weight over body weight 
(Fig. 16C&E), although the difference in the former was statistically insignificant 
(p=0.067). Subsequently, the NKA level in the myocardium of the ISO-induced 
heart failure samples was measured. The NKA concentration in failing heart was 
significantly lower than healthy controls. In contrast, animals that had received 
DR-Ab immunization exhibited an upward trend in the amount of NKA (Fig. 
16F). These data support our findings in cellular models and implicate the 
possible long-term consequence of up-regulated NKA endocytosis under high 
ROS environment. Moreover, they present in vivo evidence that the DR-Ab’s 
ability in stabilizing NKA from endocytosis may translate into higher NKA 













Figure 16. Effect of DR-Ab on isoproterenol (ISO) induced heart failure 
and NKA reduction. (A&B&D) Body weight (A), heart weight (B), and left 
ventricle weight (D) at the end of 10 weeks post the ISO injection. (C&E) 
Heart weight (C) or left ventricle weight (E) normalized against body weight. 
(F) Representative western blot (upper panel) and group analysis (lower panel) 
showing the amount of NKA in control, ISO and ISO+DR-Ab treated rat 
myocardium. n=8. Mean±SEM. *p<0.05, **p<0.01, ***p<0.001 vs control; 
#p<0.05, ##p<0.01, ###p<0.001 vs ISO.  
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Part II DR-Ab protects osteoblastic cells against oxidative injury and 
produces therapeutic effect in osteoporotic rats  
 
3.4 DR-Ab protects osteoblasts from oxidative injury 
3.4.1 DR-Ab protects against ROS-induced cytotoxicity in MC3T3-E1 
cells 
As shown in Figure 17A, MTT assay showed that pretreatment with DR-Ab (2 
μM, 60 min) attenuated MC3T3-E1 osteoblastic cell injury caused by 400-800 
µM of H2O2. The concentration of 400 μM H2O2 was therefore used in most of 
the following experiments unless otherwise stated. Time-course study showed that 
the protective effect of DR-Ab lasted for at least 24h (Fig. 17B). Increasing 
concentrations of DR-Ab from 0 to 4 µM dose-dependently protected osteoblastic 
cells from H2O2-induced injury (Fig. 17C). Morphological analysis also indicated 
that DR-Ab pretreatment prevented H2O2-induced cell shrinkage and detachment 
from the culture dish (Fig. 17D). Cell apoptosis was determined by Hoechst 
33342 staining in cells treated with H2O2 (200 μM, overnight). Exposure to H2O2 
induced apoptosis, as characterized by condensed and fragmented nuclei, a 
phenomenon much reduced in cells pretreated with DR-Ab (Fig. 17E). Treatment 
with the same amount of antibody purified from normal rat serum (NS) failed to 
produce any significant effect in the above experiments, suggesting that the 





Figure 17. Effects of DR-Ab on H2O2-induced injury in MC3T3-E1 
osteoblastic cells. (A) MTT assay showing that DR-Ab (2μM, 1h) pretreatment 
alleviated the cell injury caused by H2O2 (4h) at different concentrations. n=4 
(B-C) Time- (B) and concentration-(C) dependent effect of DR-Ab against cell 
injury caused by H2O2 (400 μM). n=6 (D) Morphological changes (shrinking 
and detachment) in H2O2–treated cells was absent in DR-Ab pretreated cells. 
(E) Cell apoptosis detected with Hoechst33342 staining. Mean±SEM. n=4. 
**p<0.01, ***p<0.001 vs control. #p<0.05, ##p<0.01, ###p<0.001 vs 





3.4.2 DR-Ab maintains differentiation potential of osteoblasts under 
oxidative stress 
Having studied the protective effect of DR-Ab in osteoblastic cells against ROS, 
it is of interest to explore whether DR-Ab could influence the differentiation 
potential of osteoblasts. Runx2, alkaline phosphatase (ALP) and bone sialoprotein 
(BSP) are genes required for osteoblast differentiation 
197-199
. As shown in Figure 
18A-C, pretreatment with DR-Ab (2 μM, 60 min) attenuated H2O2 (400 μM, 4 
h)-induced down-regulation of the above gene transcriptions. Collagen production 
is an important factor in enhancing bone density. DR-Ab also prevented the loss 
of collagen caused by H2O2 in osteoblasts in the above situation (Fig. 18D). The 
effect of DR-Ab on osteoblast terminal differentiation in long-term (21 days) 
osteoblast culture after short-term H2O2 (400 μM, 4 h) exposure on the 1
st
 day 
was then determined. Formation of mineralized matrix nodules of MC3T3-E1 
cells were determined by Alizarin red staining. Pretreatment with DR-Ab reversed 
H2O2–inhibited bone nodule formation (Fig. 18E). These data suggest that DR-Ab 







Figure 18. Effects of DR-Ab on H2O2-suppressed differentiation of 
MC3T3-E1 osteoblastic cells. (A-C). Effect of DR-Ab (2 μM, 1h) on H2O2 
(400 μM, 4 h) down-regulated mRNA levels of Runx2 (A), ALP (B) and BSP 
(C). n=4, 6, 4, respectively. (D) DR-Ab reversed the suppressed protein levels 
of collagen (n=8) in osteoblastic cells 5 days after short-term exposure to 
H2O2 (400 μM, 4 h). (E) Alizarin red staining showing that DR-Ab reversed 
H2O2–inhibited bone nodules formation on day 21 after short-term exposure to 
H2O2. Mean±SEM. *p<0.05, **p<0.01, ***p<0.001 vs control. #p<0.05, 




3.4.3 DR-Ab has no effects on the proliferation and differentiation of 
RAW264.7 osteoclast progenitor cells 
Bone turnover rate is a balance between bone formation by osteoblasts and bone 
resorption by osteoclasts. Intuitively, whether DR-Ab would have an impact on 
osteoclast proliferation and differentiation was examined. ROS have been shown 
to stimulate osteoblasts to secrete receptor activator of NF-B ligand (RANKL) 
200
, which, in turn, triggers signaling cascades that are essential for differentiation 
of monocytes/macrophages into osteoclasts 
201
. It was found that DR-Ab at 1-2 
µM failed to show any significant effect on the viability of RAW 264.7 mouse 
macrophage cells (Fig. 19A), suggesting that DR-Ab may have no effect on the 
proliferation of osteoclast pregenitors. In order to evaluate the effect of DR-Ab on 
ROS induced osteoclast differentiation, the expression and release of RANKL 
from rat osteoblasts were examined upon treatment with H2O2 and DR-Ab. H2O2 
was found to markedly up-regulate both RANKL gene expression (Fig. 19B) and 
release (Fig. 19C) in osteoblast cells. Pretreatment with DR-Ab, however, 
inhibited only RANKL release, but had no significant effect on its mRNA level. 
These data provide evidence that DR-Ab may decrease RANKL release from 
osteoblastic cells via a post-transcriptional mechanism. The effect of DR-Ab on 
RANKL-stimulated RAW264.7 cell differentiation was also studied. Exposure to 
50 ng/ml of RANKL fostered the transcription of RANK (Fig. 19D) and the 
expression of intercellular adhesion molecule 1 (ICAM-1, Fig. 19E), which is a 
characteristic of osteoclast differentiation. The presence of DR-Ab during the 
2-day differentiation induction course did not have significant impact on these 
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changes. These data support the notion that DR-Ab does not affect the 
RANKL-induced osteoclast differentiation, although it might reduce the release of 















3.4.4 Protein phosphatase 2a (PP2A) mediates the DR-Ab effect 
To reveal the mechanisms underlying the effect of DR-Ab, various protein 
kinases and phosphatases which may be involved were screened using MC3T3-E1 
osteoblast-like cells. Blockade of different protein kinases, phosphatases or ion 
channels with their inhibitors failed to abolish the effect of DR-Ab (Fig. 20A-I). 
Only when PP2A was blocked with its specific inhibitors (okadaic acid 10nM and 
cantharidin 1µM) did the protective effects of DR-Ab disappear (Fig. 20J), 
suggesting that PP2A may be the key to mediate the protective effect of DR-Ab.  
As shown in Figure. 20K, exposure to H2O2 significantly decreased PP2A activity 
in osteoblastic cells. The suppressed PP2A activity was largely reinstated by 
pretreatment with DR-Ab. Direct association seemed to exist in vivo between 
Figure 19. Effect of DR-Ab on osteoclast differentiation. (A) MTT assay 
showing DR-Ab had no effect on cell viability of RAW246.7. (B) RT-PCR 
analysis showing DR-Ab had no effect on H2O2-stimulated RANKL mRNA 
expression in MC3T3-E1 cells. n=8; (C) ELISA assay showing that DR-Ab 
inhibited H2O2-stimulated RANKL release in MC3T3-E1 cells. n=8; (D) 
Representative RT-PCR figure showing incubation of RAW264.7 cells with 
50ng/ml RANKL for 5 days significantly increased RANK transcription, 
compared to undifferentiated cells kept in normal DMEM. The presence of 
DR-Ab had no obvious effect on the RANKL-induced RANK expression. 
Medium was replaced every 2 days. n=6 (E) Immunofluorescence analysis 
depicting the RANKL-induced ICAM-1 expression in RAW246.7 cells. 
Incubation of RAW246.7 cells with 50ng/ml RANKL for 2 days stimulated 
ICAM-1 expression. Co-incubation with various concentrations of DR-Ab had 
no significant effect. n=6. Mean±SEM. *p<0.05, ***p<0.001 vs control, 




NKA and PP2A, as PP2A was co-immunoprecipitated together with NKA. H2O2 
interfered with this association of PP2A and NKA, and pretreatment with DR-Ab, 
to a great extent, restored this interaction, as reflected by the increased 
co-immunoprecipitation (Fig. 20L) in osteoblastic cells. This was confirmed by 
immunofluorescence assay that showed enhanced co-localization signals in 
DR-Ab treated osteoblastic cell membrane in comparison with the H2O2-treated 




























3.4.5 PP2A interacts with the N-terminus (amino acids 1-90) of NKA  
Furthered determination of the site where PP2A interacts with NKA was 
performed using in vitro GST pull-down assay. The constructs of different 
pGEX-6p-1 plasmids containing 6 intracellular domains of the NKA α1-sununit 
sequences were shown in Figure 21A upper panel. PP2A was only pulled down 
by the GST fusion proteins containing the first 90 amino acids of the NKA 
α1-subunit (GST-NKA-C1) (Fig. 21A lower panel). These data suggest that the 
segment of the first 90 amino acids of NKA α1-subunit is essential for the 
interaction with PP2A, a result consistent with a previous report 
171
. 
To examine whether interaction of PP2A and NKA is necessary for the 
DR-Ab-conferred protection against ROS, the interaction was interfered by 
transfecting MC3T3-E1 cells with NKA-C1 in pcDNA3.1 vector to competitively 
block the binding. Over-expression of NKA-C1, but not its empty vector, 
attenuated the protective effect of DR-Ab (Fig. 21B). These data indicate that 
Figure 20. PP2A mediates the effect of DR-Ab. Tyrphostin AG 1478 (2 μM) 
(B), DIDS (100 μM) (C), PD98059 (20 μM) (D), LY294002 (1 μM) (E), 
SP600125 (25 μM) (F), Bay 11-7082 (5 μM) (G), BPV(pic) (30 nM) (H), and 
Nifedipine (5 μM) (I) are inhibitors of EGFR tyrosine kinase, Cl channel, 
ERK1/2, AKT, JNK, NF-b, PTEN, and voltage-gated Ca2+ channel inhibitors, 
respectively. None of the above inhibitors attenuated the cytoprotective effects 
of DR-Ab. n=4. (J) Effect of PP2A inhibitors [okadaic acid (OK, 10 nM), 
cantharidin (Cant, 1 μM)] and a PP2B inhibitor [Cypermethrin (CY, 1 μM)] on 
DR-Ab-induced cytoprotection in MC3T3-E1 cells. n=6 or 7. (K) DR-Ab lifted 
the H2O2-suppressed PP2A activity. n=8. (L-M) Co-immunoprecipitation (L) 
and immunofluorescence analysis (M) showing that DR-Ab restored the 
interfered association between PP2A and NKA by H2O2. Mean±SEM. *p<0.05, 











Figure 21. PP2A interacts with the N-terminus of NKA. (A) Upper 
panel: Construct of plasmids containing 6 intracellular domains (C1-C6) of 
NKA; Lower panel: in vitro GST pull-down assay showing only GST 
fusion proteins containing the first 90 amino acids of the NKA α1-subunit 
(GST-NKA-C1) pulled down PP2A. n=12. (B) Over-expression of NKA-C1 
attenuated the protective effect of DR-Ab against H2O2. n=6. Mean±SEM. 
n=4 *p<0.05, **p<0.01, ***p<0.001 vs control, ###p<0.001 vs H2O2. 
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3.4.6 Reduction of membrane NKA during oxidative stress is mediated 
by endocytosis 
As PP2A plays a key role in the regulation of NKA recruitment from intracellular 
pool to membrane by dephosphorylating the α-subunit 171, whether DR-Ab affects 
the membrane abundance of NKA during oxidative stress was studied. 
MC3T3-E1 osteoblastic cells treated with H2O2 displayed significantly reduced 
NKA on plasma membrane, as shown by the biotin-labeled membrane protein, 
whereas DR-Ab pretreatment preserved the membrane NKA protein level (Fig. 
22A), confirming the immunostaining results shown in Figure 20M. To determine 
if enhanced endocytosis is responsible for the reduction in membrane abundance 
of NKA, endosomes were isolated and examined of their contents. Corresponding 
with the reduced plasma membrane NKA expression and function, there appeared 
to be accumulation of NKA in endosomes extracted from H2O2 treated cells. 
Incubation with DR-Ab prevented this accumulation (Fig. 22B). In sum, these 
data support that DR-Ab stabilizes cell membrane NKA, which is otherwise 























3.4.7 PP2A mediates the inhibitory effect of DR-Ab on endocytosis of 
NKA 
To confirm if endocytosis accounts for the lesser amount of NKA on membrane, 
the phosphorylation of Ser11, which triggers the internalization of the NKA in 
MC3T3-E1 cells, was detected. Exposure to H2O2 resulted in phosphorylation at 
Ser11, which was prevented by DR-Ab pretreatment (Fig. 23A). Because the 
dephosphorylation state of Ser11 is regulated by PP2A, we continued to 
investigate if PP2A mediated the anti-endocytosis effect of DR-Ab. The 
involvement of PP2A was confirmed by the observation that okadaic acid, an 
Figure 22. Effect of DR-Ab in H2O2-induced loss of membrane NKA 
via endocytosis. (A) Biotin-labeled cell surface protein showing the 
reduced NKA on cell membrane in ME3T3-E1 cells treated with H2O2. 
Incubation with DR-Ab reversed the loss of membrane NKA. n=4. (B) The 
accumulation of NKA in endosomes was prevented by DR-Ab. n=10. 
Mean±SEM. n=4 *p<0.05, **p<0.01, ***p<0.001 vs control, #p<0.05, 
##p<0.01 vs H2O2. 
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inhibitor of PP2A, abolished the DR-Ab effect in maintaining membrane NKA 
under high ROS conditions (Fig. 23B). These results strongly suggest that DR-Ab 












Figure 23. PP2A mediates the inhibitory effect of DR-Ab on NKA 
endocytosis. (A) Incubation with DR-Ab reversed H2O2-induced NKA 
Ser11 phosphorylation, n=4. (B) Okadaic acid (OK) abolished the effect of 
DR-Ab on maintaining membrane NKA expression. Mean±SEM. *p<0.05, 
**p<0.01, ***p<0.001 vs control, #p<0.05, ##p<0.01, ###p<0.001 vs H2O2 
alone, + p<0.05 vs H2O2+DR. 
 94 
 
3.4.8 Loss of NKA impairs osteoblast viability and differentiation 
capacity 
To examine the correlation of NKA with osteoblast differentiation and 
vulnerability under oxidative stress, NKA α1 subunit was knocked down by 
siRNA transfection. As shown in Figure 24A, along with NKA, the transcription 
of osteoblast differentiation markers alkaline phosphatase (ALP) and bone 
sialoprotein (BSP) was inhibited, implying the importance of NKA in the normal 
osteoblast differentiation. Furthermore, reduced NKA expression rendered the 
osteoblasts more vulnerable to oxidative stress (Fig. 24B), as compared with 
osteoblasts transfected with scrambled siRNA. Taken together, these data clearly 
pinpoint the essential role NKA plays in osteoblast differentiation, as well as 





















Figure 24. Loss of NKA impairs osteoblastic cell differentiation and 
viability. (A)  In MC3T3-E1 osteoblastic cells, knockdown of NKA by siRNA 
transfection lowered expression of NKA and osteoblast proliferation gene 
markers, ALP and BSP. n=6. (B) Cell viability measured by MTT showing that 
reduced NKA expression increased osteoblast vulnerability upon H2O2 




3.5 DR-Ab retards osteoporosis development in ovariectomized (OVX) rats  
3.5.1 DR-Ab reduces trabecular bone loss in OVX rats 
With the protective effect of DR-Ab proven in osteoblasts, the next goal was 
naturally to study the potential therapeutic effect of DR-Ab in osteoporosis in an 
OVX animal model. The majority of osteoporotic bone fractures in rat model 
occur at the trabeculae-rich metaphysic 
114
. Hence, metaphyseal tibia was chosen 
to determine the degree of osteoporosis. In vivo µCT images before and after 
treatments from the same animals are shown in Figure 25A. Trabecular bone loss 
was detected 4 weeks post the OVX surgery. Animals were then immunized 
biweekly with either peptide of the identical sequence of the NKA DR-region or 
adjuvant alone to elicit antibody production. After 4 times of immunization, rats 
injected with DR-peptide started to generate DR-Ab (Fig. 25C). With endogenous 
DR-Ab, the loss of bone due to osteoporosis was largely reversed 11 weeks after 
the OVX surgery. As visualized in Figure 25A, the trabeculae structure once 
missing in the 4
th
 week was even restored in the same animals after generation of 
DR-Ab. On the contrary, non-treated OVX rats experienced extensive bone 
loss.  It not only confirms the protective effect of DR-Ab, but also reveals the de 
novo formation of new trabeculae stimulated by the DR-Ab.  
Metaphyseal tibiae were collected 20 weeks after OVX, and scanned with high 
energy ex vivo µCT. Three-dimensional rendering of the tibial metaphyseal region 
is shown in Figure 25B. The cross-section images at Volume of Interest (VOI) 
showed a less dense trabecular mesh and a larger hollow bone marrow region in 
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OVX group compared with the healthy sham bone. The loss of trabecular bone 













3.5.2 DR-Ab preserves bone microarchitecture and improves bone 
strength in OVX rats 
The corresponding comparisons in the structural and bone mineral density (BMD) 
indices are shown in Figure 26. Trabecular bone micro-architecture and BMD of 
OVX group exhibited significant differences from the Sham group in all the 
indices measured: bone mineral density (BV/TV, Fig. 26A); bone volume ratio 
Figure 25. Effect of DR-Ab on trabecular bone loss in OVX rats. (A) 
Representative in vivo µCT images showing tibial bone loss at week 4 and 11 
after OVX surgery. (B) Representative ex vivo high resolution µCT scanning 
of the tibial metaphysis collected from rats 20 weeks post OVX surgery. (C) 
DR-Ab titer in rats of various treatment groups at week 11 after OVX surgery.  
n=4 for Sham and OVX group, n=6 in OVX+DR-Ab group. 
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(BS/BV, Fig. 26B); trabecular separation (Tb.Sp, Fig. 26C); trabecular number 
(Tb.N, Fig. 26D); trabecular thickness (Tb.Th, Fig. 26E); structural model index 
(SMI, Fig. 26F); mean BMD, (Fig. 26G), trabecular density (Tb.BMD, Fig. 26H); 
indicating the successful establishment of an osteoporosis animal model. DR-Ab 
treatment showed significant improvement in almost all parameters (Fig. 26A-H), 
suggesting that DR-Ab protects trabecular bone microarchitecture and preserves 
density against estrogen-deficiency induced osteoporosis. The tibial three-point 
bending and breaking test was also performed with the above bones. As shown in 
Figure 26I, DR-Ab treatment significantly improved the decreased maximum load 
(Fmax) in the OVX group, suggesting that activation of NKA may attenuate the 
deterioration of bone strength caused by osteoporosis. Collectively, our data 
indicate that DR-Ab may produce significant therapeutic effect against 







Figure 26. DR-Ab improved mechanical properties of the bones in OVX rats. 
(A-H) Morphology and volumetric bone mineral density measured by ex vivo µCT: 
(A) bone volume ratio (BV/TV), (B) bone surface to volume ratio (BS/BV), (C) 
trabecular separation (Tb.Sp), (D) trabecular number (Tb.N), (E) trabecular thickness 
(Tb.Th), (F) structural model index (SMI), (G) mean BMD and (H) trabecular density 
(Tb.BMD). (I) Maximum load changes of different groups measured by three-point 
bending test. Mean±SEM. n=4-8. ***p<0.001 vs sham, # p<0.05, ## p<0.01, 
###p<0.001 vs OVX. 
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3.5.3 DR-Ab reverses OVX-induced rapid bone turnover  
Serum C-telopeptide of type I collagen (CTX-1) is a biomarker representing bone 
resorption rate 
202-203
, while osteocalcin bone formation rate 
204
. As shown in 
Figure 27A&B, OVX surgery significantly increased both serum CTX-1 (Fig. 
27A) and osteocalcin (Fig. 27B), indicating the induction of high rate of bone 
turnover, which would eventually result in drastic fall in BMD and bone strength. 
The presence of DR-Ab reversed these effects, suggesting that DR-Ab slowed 
down the rapid bone turnover rate.  
As a result of retarded bone turnover deleterious to the trabecular miscrostructure, 
OVX rats treated with DR-Ab showed significant trabecular histomorphometric 
changes in right distal femurs (Fig. 27C) subjected to histological examinations. 
Notable reduction was observed in trabecular number, trabecular connection and 
trabecular bone area from the OVX rats in comparison with the sham group. 
Marrow cavity was also expanded in OVX animals. In contrast, the OVX+DR-Ab 
group exhibited better trabecular bone formation at a level comparable to the 


























Figure 27. Effect of DR-Ab on OVX-induced bone turnover. (A&B) 
Serum levels of bone resorption marker CTX-1 (A) and bone formation 
marker osteocalcin (B) in OVX rats 20 weeks after OVX surgery. 
Mean±SEM. n=4 for Sham and OVX group, n=6 in OVX+DR-Ab group. 
*p<0.05 ***p<0.001 vs Sham; #p<0.05 vs OVX group. (C) Haemotoxylin 
and eosin (H&E) staining of right femur sections from sham, OVX, and 




3.5.4 NKA expression is reduced in osteoblasts in osteoporotic bones 
To verify our in vitro findings that NKA expression was reduced under oxidative 
stress and that DR-Ab effectively inhibited the removal of surface NKA, the level 
of NKA expression was examined in bones of OVX rats. Immunostaining in 
subchondral bone revealed loss of NKA in osteoblasts, which were adjacent to the 
surface of trabecular bones (arrow indicated), as compared with the sham group 
(Fig. 28A). The reduction in NKA expression, however, was not observed in 
OVX-DR-Ab group (Fig. 28A). Surface NKA density in osteoblasts was also 
assessed in primary cultured osteoblasts isolated from long bones of OVX rats at 
the end of the entire experiment (week 20 post OVX surgery). Relative to 
osteoblast from sham rats, NKA abundance on plasma membrane exhibited 
drastic decline in OVX rats’ osteoblasts (Fig. 28B). There was a slightly increase 
in the level of surface NKA in osteoblasts from the OVX-DR-Ab rats (Fig. 28B). 
These findings suggest that in OVX induced osteoporosis, NKA expression is 
lowered in osteoblasts, probably as a result of long term enhanced removal of the 
protein from the plasma membrane. Circulating DR-Ab may reverse such trend by 
regulating the erratic trafficking cycle and degradation of NKA. The expression 
and function of NKA is thus preserved by DR-Ab, which, in turn, protects 















Figure 28. Effect of DR-Ab on reduced NKA expression in OVX rat bones. 
(A) Representative immunohistochemistry images showing that DR-Ab 
prevented the reduced NKA expression in rat right femur sections 20 weeks 
after OVX surgery. Scale bar: 0.1mm. n=4 for Sham and OVX group, n=6 in 
OVX+DR-Ab group. (B)  Biotin-labeled NKA protein on plasma membrane 
of primary cultured osteoblasts from rats undergone sham, OVX, and 
OVX+DR-Ab treatments (20 weeks after OVX surgery).  
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3.5.5 Long term presence of DR-Ab does not cause toxicity in 
cardiovascular system 
Given the high expression level of NKA in heart and the inotropic and 
cardioprotective effect of DR-Ab, careful attention was paid to the potential toxic 
effects of DR-Ab in the cardiovascular system of rats that had undergone long 
term immunization scheme. After the development of DR-Ab in the OVX rats (11 
weeks post surgery), the immunization procedure was continued, only at a lower 
frequency of once a month, to maintain a relatively high antibody titer, the result 
of which is shown in Fig. 29J. In rats immunized with DR-peptide, a strong 
immune response was elicited, as suggested by the significantly higher titer of 
circulating DR-Ab compared with sham and OVX groups. When animals were 
sacrificed at week 20 post surgery, the blood pressure and somatic and heart 
weights were measured to evaluate the effect of long term exposure to DR-Ab in 
cardiovascular system. No obvious changes were observed in blood pressure (Fig. 
29A), body (Fig. 29B), heart (Fig. 29C), ventricle (Fig. 29E) or left ventricle (Fig. 
29F) weight. There were no significant differences in the normalized heart (Fig. 
29D), or left ventricle (Fig. 29G&H) weight as well. The left ventricular wall 
appeared to be of comparable thickness among various treatment groups (Fig. 
29I). Together, there seemed to be no signs of abnormality in the cardiovascular 
















Figure 29. Effect of long term (4 month) circulating DR-Ab on the cardiac 
system in OVX rats. The cardiovascular parameters measured include blood 
pressure (A), body weight (B), heart weight (C), heart weight/body weight (D), 
ventricle weight (E), left ventricle weight (F), left ventricle weight/body weight 
(G), left ventricle weight/heart weight (H), and left ventricle thickness (I). No 
significant difference was found in any of the above parameters. (J) DR-Ab titer 









CHAPTER 4  




















Discussion and conclusion 
 
4.1 Summary of the current findings  
In this thesis, evidence is presented that the NKA is a key target of ROS under 
physiological and pathological conditions. The resultant loss of NKA and 
subsequent loss of viable cardiomyocytes and osteblasts attribute to the 
development of heart failure and osteoporosis. A polyclonal antibody binding to 
the DR-region of NKA (DR-Ab), via stabilizing the NKA membrane expression, 
not only confers strong protection against oxidative damage in vitro, but also 
demonstrates therapeutic value in animals with heart failure or osteoporosis (Fig. 
30). Therefore, the current project reveals the role of NKA in cardiac and skeletal 
pathophysiology, and proposes a novel approach for the management of heart 
failure and osteoporosis.   
 
4.2 NKA and DR-Ab  




) of H7-H8 domain in 
-subunit is an important activation site of NKA that is capable of promoting the 
catalytic function of the enzyme and regulating cardiac contractility 
154
. It has 
been previously reported that activation of NKA with SSA412 (rabbit derived 
DR-region specific antibody) produces positive inotropic effect via activation of 
Src/ERK1/2 pathway 
156
. In this study, a rat polyclonal antibody that specifically 
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targets the DR-region (DR-Ab) was first generated by immunization of the 
animals with peptide of the same amino acid sequence and purification of the 
desired antibody from rat sera. In most experiments, serum from rats which were 
immunized with only adjuvant (normal serum) was employed to purify normal rat 
antibody as a control. The ability of the antibody to bind to and activate the NKA 
was first examined by immunoblotting and NKA activity assay. It was found that 
DR-Ab readily bound to and activated NKA in a dose-dependent fashion. These 








Figure 30. Schematic illustration showing the effect of DR-Ab. Elevated 
ROS level may stimulate PKC, which phosphorylates the critical serine residue 
on NKA alpha subunit and induces its endocytosis. The loss of functional NKA, 
in the long run, contributes to loss of viable cardiomyocytes and osteoblasts and 
the development of heart failure and osteoporosis. DR-Ab, possibly through 
inducing conformational change of N-terminus of NKA (i.e. NKAaa1-90), 
enhances the interaction of NKA with PP2A, which dephosphorylates NKA and 
prevents its endocytosis during oxidative stress. Consequently, DR-Ab 
preserves viable cardiomyocytes and osteoblasts, and improves cardiac function 




4.3 Protective effect of DR-Ab against oxidative damage in cardiomyocyte and 
osteoblast  
A wealth of studies has implicated the involvement of ROS in various 
physiological and pathological events in the cardiovascular system. ROS 
participate in the redox signaling in normal healthy cardiomyocytes and, when 
disregulated, pose oxidative challenge to viable myocardium, thus underlying the 
development of a series of cardiac diseases such as ischemia/reperfusion injury, 
myocardial infarction, cardiac hypertrophy, and heart failure 
205-210
.  
In terms of osteoporosis, most attention has been devoted to the classical 
postmenopausal estrogen deficiency model. However, a growing body of 
evidence has demonstrated the deleterious effect of age-related ROS 
accumulation in the skeletal system, highlighting the complexity of the 
pathogenesis of osteoporosis and pinpointing ROS as a key factor along the 
process 
211-214




Although as an important intracellular second messenger, lower level of ROS 
exert specific and subtle regulation of signaling pathways under physiological 
conditions, consensus has been reached that excessive amount of ROS, 
endogenous or exogenous, would result in oxidative damages at cellular level, 
which eventually leads to the failure in these two systems to properly function.  
Given the pivotal role of ROS in the development of cardiac and skeletal 
conditions, it seems only reasonable to begin the present study with the protective 
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effect of DR-Ab against oxidative stress in cardiomyocytes and bone-forming 
osteoblasts. Incubation with DR-Ab was found to effectively reduce 
H2O2-induced necrosis and apoptosis in both AC16 human cardiomyocyte cell 
line and MC3T3-E1 mouse osteoblastic cell line. In the scope of the cardiac 
system, the above findings were extrapolated to primary cultured adult rat 
cardiomyocytes subjected to ischemia and reperfusion injury (during which large 
amount of ROS are generated). DR-Ab, again, improved the viability of 
individual cardiomyocytes with or without simulated ischemia and reperfusion 
treatment. In bones, experiments focused on the effect of DR-Ab on osteoblastic 
differentiation. In addition to the protection against H2O2-induced cytotoxicity, 
DR-Ab also restored the transcription of osteoblast differentiation marker genes, 
e.g. Runx2, ALP and BSP, which were inhibited by ROS. Collagen production is 
an important factor in enhancing bone density. It was found that DR-Ab 
prevented the loss of collagen caused by H2O2 in osteoblasts. This is further 
supported by alizarin red staining assay which showed that DR-Ab significantly 
alleviated H2O2-suppressed nodule formation. Taken together, the above data 
clearly suggest that DR-Ab may protect cardiomyocytes and osteoblasts against 
cellular injury, and promote differentiation of the latter under oxidative 
conditions.   
 
4.4 NKA as a target of ROS in cardiovascular and skeletal pathologies  
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As one of the oldest ion pumps discovered, numerous reports have demonstrated 
NKA’s classical role as an active transporter, as well as the more recently realized 
signal transducer function 
216-218
. What is less known, perhaps, is that NKA is a 
target protein of ROS, which interferes with NKA function by reducing NKA 
membrane expression and/or activity 
149-150,176,219-220
. This is confirmed in 
transgenic mutant SOD1 mice, and ischemia-reperfusion treated A549 human 
alveolar basal epithelial cells and rat alveolar epithelial type II cells 
149,178
.  
The presence and abundance of plasma membrane proteins is finely regulated by 
a balance between anterograde and retrograde vesicular trafficking. The 
disruption of such balance very often results in deleterious cellular consequences. 
It has been recognized that the phosphorylation of critical species-specific serine 
residues on the N-terminal of NKA α subunit plays a pivotal role in determining 
the fate of the enzyme in the trafficking cycle 
150,171,221-223
. The best studied PKC 
phosphorylation site is Ser18 
224
, but this residue is unique to rat. Phosphorylation 
of Ser 18 triggers the endocytosis of NKA during oxidative stress 
169,178,225-229
. 
Other report suggests phosphorylation of ubiquitously expressed Ser11 
167
 is 
required in the regulation of endocytosis of NKA. Mutation of Ser11 to an alanine 
reduces its phosphorylation by PKC 
167,230-231
. The inconsistencies may have 
arisen from different stimuli used to trigger endocytosis in different cell systems, 
as well as different PKC isoforms involved in these studies.  
Despite differences in the details of the experiments, it is generally accepted that 
phosphorylation of NKA by PKC marks the initiation of endocytosis, while 





. It also appears that PP2A, but not other protein 
phosphatase, mediates the dephosphorylation of NKA 
233,235
, through multi-site 
direct interaction with NKA 
187
. And this interaction is absent with the 






. In this study, it was evident that the 
density of NKA protein on cell surface, together with the activity, were largely 
reduced when cells were oxidatively challenged with either exogenous 
introduction of H2O2 or endogenous generation of ROS during ischemia and 
reperfusion. Furthermore, in line with previous reports, PKCζ also appeared to be 
activated, while PP2A inhibited under oxidative stress 
236-237
, which functioned in 
concert to contribute to the phosphorylation of Ser11 in MC3T3-E1 
osteoblast-like cells or Ser18 in H9C2 cardiomyocytes. Together, they provide 
explanation for the reduced cell surface NKA concentration and its enrichment in 
endosomes when cells were treated with H2O2. Incubation with DR-Ab failed to 
affect the PKCζ activation, but restored the suppressed PP2A activity. 
Furthermore, blockade of PP2A abolished the effect of DR-Ab on NKA 
dephosphorylation and subsequent cytoprotection, suggesting that endocytosis of 
NKA may be a result of inefficient dephosphorylation by PP2A during oxidative 
stress, and that preservation of membrane NKA expression mediates the 
cytoprotective effect of DR-Ab. 
Co-immunoprecipitation and fluorescence co-localization results supported that 
the modulation of PP2A activity by DR-Ab was achieved by direct interaction 
between NKA and PP2A, which has been documented in literature 
171,187
. To go 
one step further, only the GST fusion protein containing the first 90 amino acids 
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of NKA pulled PP2A down, narrowing down the potential interaction sites to this 
region. It is possible that DR-Ab may induce conformational change of 
N-terminus of NKA (i.e. NKAaa1-90) and, therefore, enhance the association 
between NKA and PP2A. This interaction can be partly blocked by 
overexpressing NKAaa1-90. Thus, these data suggest that PP2A activation caused 
by DR-Ab may dephosphorylate NKA and, in turn, prevent it from being 
endocytosed during oxidative stress.  
It is hypothesized that the unbalanced trafficking of NKA caused by its sustained 
enhanced removal and degradation would eventually give rise to the reduced 
NKA level in unhealthy myocardium and bone tissues suffering from prolonged 
oxidative stress. Indeed, the NKA protein expression in isoproterenol-induced rat 
heart failure samples was compromised, which is consistent with multiple other 
accounts documenting the reduction of NKA in heart failure patients 
96-103
. On the 
other hand, NKA expression in osteoporotic bones is more complicated.  Similar 
to heart failure, the NKA expression was reduced, as visualized by 
immunostaining of decalcified rat femur sections. However, since the 
osteoporosis model was established with ovariectomized rats, there remains a 
question as to whether estrogen deficiency also underlies the decreased NKA 
concentration. Supplements to restore physiological concentrations of 
17-estradiol resulted in significantly increased NKA expression and activity. 
This is supported by a previous study in which estrogen replacement recovered 
OVX-induced down-regulation of protein expression and activity of NKA in the 
renal cortex 
238
. In addition, OVX was shown to induce membrane NKA loss in 
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the primary cultured osteoblast isolated from animals with osteoporosis. Our data 
suggest that estrogen deficiency and accumulated ROS, both key factors in the 
pathogenesis of osteoporosis, may inhibit NKA expression and activity, leading to 
the downregulation of NKA in osteoblasts in osteoporotic bones. In the animal 
models of both heart failure and osteoporosis, the loss of NKA was mitigated by 
circulating DR-Ab. These in vivo findings are consistent with the cellular results, 
and support the hypothesis that reduced NKA expression caused by ROS and 
estrogen-deficiency may be responsible for heart failure and osteoporosis. This 
hypothesis was further supported by the increased vulnerability of 
cardiomyocytes and osteoblasts to H2O2 when NKA was knocked down with 
siRNA. The lowering of endogenous NKA also affected the differentiation 
potential of osteoblasts.  
 
4.5 Therapeutic effect of DR-Ab in heart failure 
On the basis that ROS-induced loss of NKA was closely associated with the 
development of heart failure and osteoporosis, and that DR-Ab stabilized NKA 
expression under oxidative stress both in vitro and in vivo, additional experiments 
were performed to explore the potential therapeutic value of DR-Ab in the 
aforementioned diseases.  
Although timely myocardial reperfusion salvages viable myocardium from 
ischemia attack caused by occlusion of the coronary artery, reintroduction of blood 





. Several mediators have been identified by various 
studies to contribute to the detrimental effects of ischemia-reperfusion injury. The 
most frequently cited ones include oxidative stress 
57,241-243
, calcium overload 
244-246
 
amongst others like microvascular injury 
242,247
, and rapid pH change 
248-249
. Acting 
in concert, these factors lead to the common manifestations of 
ischemia-reperfusion injury 
250-251
, namely myocardial stunning 
252-254
, 
microvascular and endothelial damage 
247,255-257
, and, perhaps most severely, 
myocyte necrosis 
58,258
. Due to the limited regenerative potential of heart cells, the 
irreversible ischemia-reperfusion injuries impair cardiac contractile machinery and 
give rise to heart failure. Here the protective effect of DR-Ab against ischemia and 
reperfusion damage was demonstrated using isolated rat hearts. Incubation with 
DR-Ab prior to the interruption and resumption of perfusate preserved the viability 
of the myocardium and reduced the infarct size than hearts perfused without 
DR-Ab. Moreover, in DR-Ab perfused hearts, the contractile function injured by 
ischemia and reperfusion treatment showed rapid recovery to levels comparable to 
before the experiments. The improved contractile function is likely to be mediated 
not only by the cellular death, but also the positive inotropic effect of DR-Ab, as 
isolated cardiomyocytes were found to contract stronger in the presence of DR-Ab. 
Accompanying the positive inotropy was the increased Ca
2+
 influx to the isolated 
cardiomyocytes during contraction cycle. The discovery that DR region-specific 
antibody induced positive inotropy and elevated intracellular Ca
2+
 concentration 





Based on the above positive inotropic and cardioprotective effects of DR-Ab, it is 
reasonable to postulate that DR-Ab may be potentially used to treat heart failure. 
In the present study, a heart failure model was created by ligation of the left 
anterior descending coronary artery to induce myocardial infarction in 
Sprague-Dawley rats. Two months after the myocardial infarction surgery, overt 
heart failure occurred in animals with a myocardial damage of 20% of the total 
size of heart. These rats were also well characterized by cardiac haemodynamic 
changes such as decreased LVDP, increased LVeDP and left ventricular dilatation. 
This is consistent with the heart failure reported in the literature 
259
. After the 
successful establishment of heart failure model, the therapeutic effect of DR-Ab 
on failing hearts was studied. DR-Ab significantly stimulated the injured heart 
contractile function by increasing LVDP and ±dp/dt and, in the mean time, 
decreasing LVeDP, indicating that DR-Ab may be useful to stimulate heart 
contractile function by increasing the cardiac contractile and relaxation 
efficiencies. Another positive change induced by DR-Ab is the reversed 
ventricular hypertrophy due to toxic cardiomyopathy in the ISO-treated rats. The 
reduction in ventricular mass provides additional evidence that DR-Ab prevents 
adverse remodeling of myocardium.  
In sum, DR-Ab strengthened cardiomyocytes’ defense against oxidative damage 
via preservation of functional NKA on plasma membrane. DR-Ab may also 
induce positive inotropy via increased calcium influx. Together, the in vivo 
beneficial effects of DR-Ab are the outcome of the concurrent actions of 
improved survival of the contractile apparatus and the enhanced contractility. 
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Additional finding of the beneficial effect of DR-Ab in reversing ventricular 
hypertrophy further adds onto our understanding of its potential therapeutic 
applications.   
 
4.6 Therapeutic effect of DR-Ab in osteoporosis  
In this study, the potential therapeutic effect of DR-Ab on osteoporosis was 
investigated using the OVX animal model. Biochemical analysis of bone 
resorption marker CTX-1 and formation marker osteocalcin in serum showed 
stimulated bone formation and slowed down bone turnover rate in rats receiving 
DR-Ab treatment. These results are consistent with our cellular studies. In vivo 
μCT scanning at different time points of the same animals demonstrated new bone 
formation in already osteoporotic bones. H&E staining revealed that DR-Ab, to a 
large extent, reversed the notable trabecular histomorphometric changes in bones 
of OVX rats.  
The micro-structure of rat tibia from the OVX group revealed by μCT images 
demonstrated significant reduction in bone volume fraction (BV/TV), trabecular 
number (Tb.N) and trabecular thickness (Tb.Th) 20 weeks after surgery compared 
to the sham surgery group. These changes revealed a severe loss of bony material 
in OVX group, which was in accordance with significant increase in bone surface 
to volume ration (BS/BV) and separation (Tb.Sp) between adjacent trabeculae. 
Moreover, the morphology of the existing trabeculae struts appeared more 
rod-like instead of plate-like in shape, as reflected by a rise in structural model 
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index (SMI). A leveling off of micro-architectural changes was observed in 
DR-Ab treated bone. The positive effect of DR-Ab treatment occurred in 
preservation of trabecular bone quantity in terms of significantly increased 
BV/TV and Tb.N. The above mentioned positive alterations rendered by DR-Ab 
resulted in net gain in Tb.BMD. In line with the mBMD result, tibia from sham 
and DR-Ab treatment group had significantly higher maximum load (Fmax) than 
OVX group. This means that the DR-Ab treatment would allow the bone to 
withstand higher load before fracturing as compared to the untreated bone. Taken 
together, these findings indicate that activation of NKA may be an efficient route 
to treat osteoporosis. 
Bone turnover rate is a balance between bone formation by osteoblasts and bone 
resorption by osteoclasts. Intuitively, the impact of DR-Ab on osteoclast 
differentiation was measured. Osteoblasts, when under oxidative challenge, 
express RANKL to stimulate osteoclast differentiation. It was noted that although 
DR-Ab failed to suppress the ROS-induced elevated transcription of RANKL in 
osteoblasts, it did inhibit its release. RAW246.7 cells, in the presence of RANKL, 
differentiate into osteoclasts. Examination of two differentiation parameters, 
RANK transcription and ICAM-1 expression, showed no significant change upon 
treatment with DR-Ab. More studies are needed to elucidate the detailed role that 
DR-Ab plays in osteoblast and osteoclast differentiation, but our data indicate that 




Overall, the favorable responses induced by DR-Ab in osteoporotic bones are 
mainly mediated by the increased bone formation. NKA is lost under oxidative 
stress and/or estrogen deficiency, leading to suppressed osteoblast proliferation 
and differentiation. DR-Ab promotes the anabolic effect of osteoblasts by 
maintaining functional NKA.  
 
4.7 Limitations and future studies 
Despite the conceptual advances made by this study, there are several questions to 
be answered. First of all, it remains unclear how H2O2-induced endocytosis, a 
short term regulatory action of the membrane abundance of NKA, can translate 
into a long term, permanent reduction in expression, as seen in failing 
myocardium and osteoporotic bones. Cell surface NKA density reflects the 
balance between its delivery to and internalization from the plasma membrane. 
Since elevated ROS have been implicated in human heart failure and osteoporosis 
throughout the lengthy progression of diseases, whether as a pathological 
consequence or simply an age-related physiological process, it is well possible 
that the sustained high levels of ROS during the adverse remodelling could have 
tilted this balance by a constant upregulation of NKA endocytosis. This can be 
achieved by continual modulations of NKA phosphorylation status as a result of 
higher basal ROS level, eventually leading to the long-term reduction in NKA 
expression. Experiment evidence is needed to support this hypothesis before a 
more definitive statement can be made. 
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In addition, direct evidence linking the preserved surface NKA with the 
cytoprotective effect of DR-Ab is lacking. Although DR Ab-induced 
cardioprotection is associated with a stabilized membrane NKA expression in this 
study, the exact relationship between the two factors is unclear. Given the crucial 
role of NKA in cellular processes (as active transporter and signal transducer), it 
is speculated that maintaining NKA level at a physiological range may be able to 
compensate the loss of NKA activity both as an ion pump and signal transducer, 
therefore alleviating the oxidative injury. One possible way to establish the 
missing link is to manipulate NKA endocytosis and evaluate the subsequent 
change in cellular oxidative damage. Inhibitors of endocytosis 
263
 or introduction 
of endocytosis-resistant mutant NKA might be appropriate tools for this study. 
Also, as the cardioprotective effect of DR-Ab is probably multifaceted due to the 
complicated NKA-associated signaling complex. Despite the accumulating 
evidence of NKA-mediated signaling mechanism, no reports have associated such 
signaling pathways with CHF. Rather, studies have focused on the inhibitory 
effect of cardiac glycosides on NKA in failing myocardium and revealed 
consistently that the severity of CHF correlates with the plasma level of 
endogenenous cardiac glycoside 
264
, a conclusion in line with the findings in this 
thesis. Lee et al. reported that activating NKA triggers Src-ERK pathway to 
induce positive inotropy 
156
, which still provides no direct link between NKA 
signaling and CHF. Nevertheless, it should not be overlooked that the 
NKA-mediated signaling pathways may play a role in development of CHF. It is 
possible that by maintaining the density of the NKA on cell surface, some 
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pro-survival signaling pathways could be activated to promote cardiomyocyte 
viability. However, these theories could only be validated by experimental 
evidence. 
The notion of using DR-region specific antibody as therapeutics poses a number 
of concerns. First of all, the current DR-Ab is a rat polyclonal antibody. As a 
result, the antibody-antigen affinity is likely to vary significantly across batches of 
production. Moreover, antibody of rat origin will be recognized as foreign and be 
eliminated by patients’ immune system. In addition, the rats were immunized 
using DR peptide, limiting their specificity to the primary amino acid sequence 
rather than the 3D structure of the epitope present in cell membrane. Last but not 
least, the concentration of the antibody used in this project (2 μM) is significantly 
higher than that of a typical therapeutic monoclonal antibody in clinical setting 
(~0.07-0.7 μM) 265. A few reasons might be causing the elevated concentration. 
First of all, the purified DR-Ab contained large amount of normal IgG. Although 
the presence of these immunoglobulins was controlled for using pooled IgG 
purified from normal rat serum following the same protocol, the accurate 
calculation of DR-Ab concentration was impeded. The heterogeneity of 
polyclonal DR-Ab may be another reason behind the high dosing. Multiple 
antibodies targeting at different epitopes exhibit different efficacies, increasing 
the concentration required to elicit a favourable response. A good solution to 
solve the above problems is to develop monoclonal antibody using gene gun 
delivered DNA-based immunization 
266-267
 followed by antibody engineering 
process to make it less immunogenic (e.g. chimeric or humanized) and more 
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sensitive to properly folded 3D protein structures. Perhaps better still is the 
exploitation of the phage display technique 
268-269
 or the more recent transgenic 
humanized mice 
270
 to generate fully human monoclonal antibody (mAb).  
Even human mAb-based treatment could prove problematic 
265
. One of the major 
limitations is the large size of mAbs, which affects its tissue penetration 
(approxiamately 80% remains in circulation) 
271
, as well as hinders its clearance 
from kidney glomerular filtration 
272
, the latter of which contributes to its long 
serum half-life and may become a concern for over dosage. To circumvent these 
limitations, it might be a good idea to express the ectodomain of the NKA 
β-subunit that interacts with the α-subunit, under the hypothesis that such 
truncated β-subunit would function similarly as DR-Ab to compensate the loss of 
NKA expression and activity in disease models. Since the DR-region is one of the 
four α-β interaction sites, it is possible that truncated forms of β-subunit that 
recognized other interaction sites could mimic the effect of DR-Ab. In fact, a 




4.8 Conclusion  
In conclusion, NKA was shown to be a target of ROS and the resultant loss of the 
enzyme was closely associated with cardiac and skeletal pathologies. DR-Ab 
stabilized the number of functional NKA by regulating its aberrant endocytosis 
under oxidative stress via a PP2A dependent mechanism. The resultant restoration 
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of the NKA expression and activity, in turn, alleviated the oxidative injury in 
cardiomyocytes and osteoblasts. 
In heart, DR-Ab significantly reduced the infarct size and improved the impaired 
heart contractile function during ischemia and heart failure. The cardioprotective 
and positive inotropic properties of DR-Ab clearly indicate its therapeutic 
potential to treat heart failure. Furthermore, unlike traditional inotropic agents 
such as digitalis-like compounds, DR-Ab is far less arrhythmiogenic due to more 
efficient calcium handling.  
In bone, the current project demonstrated for the first time an important 
physiological function of NKA in osteoblast proliferation, differentiation, and 
viability. Moreover, the intriguing discovery that both oxidative stress and 
estrogen deficiency resulted in impaired NKA expression and function further 
pinpoints NKA’s critical role in the development of osteoporosis. Circulating 
DR-Ab effectively rescued the deterioration of trabecular micro-architecture and 
increased the bone strength.    
While constant research focus has been devoted to explore new targets involved 
in heart disease and osteoporosis, NKA, an old enzyme, has emerged as a key 
player that deserves more attention in cardiac and skeletal systems. The current 
study has revealed the utmost importance of preserving NKA in the battle against 
heart failure and osteoporosis. Admittedly, much work needs to be completed to 
fully elucidate the protective effect of DR-Ab. Nevertheless, our findings provide 
new mechanistic insight to the pathogenesis of heart failure and osteoporosis, and 
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